
<p>{{dablink}}</p>
<p>{{Infobox_Disease}}</p>
<p>Acute <b>myocardial infarction</b> (<b>AMI</b> or <b>MI</b>), more commonly known as a <b>heart attack</b>, is a medical condition that occurs when the <a href="/wiki/Blood_flow" id="w">blood supply</a> to a part of the <a href="/wiki/Heart" id="w">heart</a> is interrupted, most commonly due to rupture of a <a href="/wiki/Vulnerable_plaque" id="w">vulnerable plaque</a>. The resulting <a href="/wiki/Ischemia" id="w">ischemia</a> or <a href="/wiki/Hypoxia_(medical)" id="w">oxygen shortage</a> causes damage and potential death of heart tissue. It is a <a href="/wiki/Medical_emergency" id="w">medical emergency</a>, and the leading cause of death for both men and women all over the world.<sup id="_ref-WHO-2002_a" class="reference"><a href="#_note-WHO-2002" title="">[1]</a></sup>  Important <a href="/wiki/Risk_factor" id="w">risk factors</a> are a previous history of vascular disease such as <a href="/wiki/Atherosclerosis" id="w">atherosclerotic</a> <a href="/wiki/Coronary_heart_disease" id="w">coronary heart disease</a> and/or <a href="/wiki/Angina_pectoris" id="w">angina</a>, a previous heart attack or <a href="/wiki/Stroke" id="w">stroke</a>, any previous episodes of abnormal heart rhythms or <a href="/wiki/Fainting" id="w">syncope</a>, older age&#8212;especially men over 40 and women over 50, <a href="/wiki/Tobacco_smoking" id="w">smoking</a>, excessive alcohol consumption, the abuse of certain drugs, high triglyceride levels, high <a href="/wiki/Low_density_lipoprotein" id="w">LDL</a> (&#34;Low-density lipoprotein&#34;) and low <a href="/wiki/High_density_lipoprotein" id="w">HDL</a> (&#34;High density lipoprotein&#34;), <a href="/wiki/Diabetes_mellitus" id="w">diabetes</a>, <a href="/wiki/Hypertension" id="w">high blood pressure</a>,  <a href="/wiki/Obesity" id="w">obesity</a>, and chronically high levels of stress in certain persons.</p>
<p>The term <i>myocardial infarction</i> is derived from <i><a href="/wiki/Myocardium" id="w">myocardium</a></i> (the heart muscle) and <i><a href="/wiki/Infarction" id="w">infarction</a></i> (tissue death due to oxygen starvation). The phrase &#34;heart attack&#34; is sometimes used incorrectly to describe <a href="/wiki/Sudden_cardiac_death" id="w">sudden cardiac death</a>, which may or may not be the result of acute myocardial infarction.</p>
<p>Classical symptoms of acute myocardial infarction include <a href="/wiki/Chest_pain" id="w">chest pain</a> (typically radiating to the left arm), <a href="/wiki/Dyspnea" id="w">shortness of breath</a>, <a href="/wiki/Nausea" id="w">nausea</a>, <a href="/wiki/Vomiting" id="w">vomiting</a>, <a href="/wiki/Palpitation" id="w">palpitations</a>, <a href="/wiki/Sweating" id="w">sweating</a>, and <a href="/wiki/Anxiety" id="w">anxiety</a>. Patients frequently feel suddenly ill. Women often experience different symptoms from men. The most common symptoms of MI in women include shortness of breath, weakness, and <a href="/wiki/Fatigue_(physical)" id="w">fatigue</a>. Approximately one third of all myocardial infarctions are silent, without chest pain or other symptoms.</p>
<p>Immediate treatment for suspected acute myocardial infarction includes <a href="/wiki/Oxygen_therapy" id="w">oxygen</a>, <a href="/wiki/Aspirin" id="w">aspirin</a>, <a href="/wiki/Glyceryl_trinitrate_(pharmacology)" id="w">glyceryl trinitrate</a> and <a href="/wiki/Analgesia" id="w">pain relief</a>, usually <a href="/wiki/Morphine_sulfate" id="w">morphine sulfate</a>. The patient will receive a number of diagnostic tests, such as an <a href="/wiki/Electrocardiogram" id="w">electrocardiogram</a> (ECG, EKG), a chest <a href="/wiki/X-ray" id="w">X-ray</a> and <a href="/wiki/Blood_test" id="w">blood tests</a> to detect elevated <a href="/wiki/Creatine_kinase" id="w">creatine kinase</a> or <a href="/wiki/Troponin" id="w">troponin</a> levels (these are chemical markers released by damaged tissues, especially the myocardium). Further treatment may include either <a href="/wiki/Medication" id="w">medications</a> to <a href="/wiki/Thrombolysis" id="w">break down blood clots</a> that block the blood flow to the heart, or mechanically restoring the flow by <a href="/wiki/Angioplasty" id="w">dilatation</a> or <a href="/wiki/Coronary_artery_bypass_surgery" id="w">bypass surgery</a> of the blocked coronary artery. <a href="/wiki/Coronary_care_unit" id="w">Coronary care unit</a> admission allows rapid and safe treatment of complications such as <a href="/wiki/Cardiac_arrhythmia" id="w">abnormal heart rhythms</a>.</p>
<a id="Epidemiology" name="Epidemiology"></a><h1>Epidemiology</h1>
<p>Myocardial infarction is a common presentation of <a href="/wiki/Ischemic_heart_disease" id="w">ischemic heart disease</a>. The WHO estimated that in 2002, 12.6 percent of deaths worldwide were from ischemic heart disease.<sup id="_ref-WHO-2002_b" class="reference"><a href="#_note-WHO-2002" title="">[1]</a></sup> Ischemic heart disease is the leading cause of death in developed countries, but third to <a href="/wiki/AIDS" id="w">AIDS</a> and <a href="/wiki/Lower_respiratory_infection" id="w">lower respiratory infections</a> in developing countries.<sup id="_ref-UCatlas_a" class="reference"><a href="#_note-UCatlas" title="">[2]</a></sup></p>
<p>In the <a href="/wiki/United_States" id="w">United States</a>, <a href="/wiki/Heart_disease" id="w">diseases of the heart</a> are the <a href="/wiki/List_of_causes_of_death_by_rate" id="w">leading cause of death</a>, causing a higher <a href="/wiki/Death" id="w">mortality</a> than <a href="/wiki/Cancer" id="w">cancer</a> (<a href="/wiki/Malignant" id="w">malignant</a> <a href="/wiki/Neoplasia" id="w">neoplasms</a>).<sup id="_ref-causesofdeath_a" class="reference"><a href="#_note-causesofdeath" title="">[3]</a></sup>  <a href="/wiki/Coronary_heart_disease" id="w">Coronary heart disease</a> is responsible for 1 in 5 deaths in the U.S.. Some 7,200,000 men and 6,000,000 women are living with some form of coronary heart disease. 1,200,000 people suffer a (new or recurrent) coronary attack every year, and about 40% of them die as a result of the attack.<sup id="_ref-AHAstats_a" class="reference"><a href="#_note-AHAstats" title="">[4]</a></sup>  This means that roughly every 65 seconds, an American dies of a coronary event.</p>
<p>In <a href="/wiki/India" id="w">India</a>, cardiovascular disease (CVD) is the leading cause of death.<sup id="_ref-mukhPred_a" class="reference"><a href="#_note-mukhPred" title="">[5]</a></sup> The deaths due to CVD in India were 32% of all deaths in 2007 and are expected to rise from 1.17 million in 1990 and 1.59 million in 2000 to 2.03 million in 2010.<sup id="_ref-ghafBurd_a" class="reference"><a href="#_note-ghafBurd" title="">[6]</a></sup>  Although a relatively new epidemic in India, it has quickly become a major health issue with deaths due to CVD expected to double during 1985-2015.<sup id="_ref-rastPhys_a" class="reference"><a href="#_note-rastPhys" title="">[7]</a></sup><sup id="_ref-GuptEsca_a" class="reference"><a href="#_note-GuptEsca" title="">[8]</a></sup>  Mortality estimates due to CVD vary widely by state, ranging from 10% in Meghalaya to 49% in Punjab (percentage of all deaths).  Punjab (49%), Goa (42%), Tamil Nadu (36%) and Andhra Pradesh (31%) have the highest CVD related mortality estimates.<sup id="_ref-guptCorr_a" class="reference"><a href="#_note-guptCorr" title="">[9]</a></sup>  State-wise differences are correlated with prevalence of specific dietary risk factors in the states.  Moderate physical exercise is associated with reduced incidence of CVD in India (those who exercise have less than half the risk of those who don&#39;t).<sup id="_ref-rastPhys_b" class="reference"><a href="#_note-rastPhys" title="">[7]</a></sup>  CVD also affects Indians at a younger age (in their 30s and 40s) than is typical in other countries.</p>

<a id="Risk_factors" name="Risk_factors"></a><h2>Risk factors</h2>
<p>Risk factors for <a href="/wiki/Atherosclerosis" id="w">atherosclerosis</a> are generally risk factors for myocardial infarction:
</p>
<ul>
<li><a href="/wiki/Old_age" id="w">Older age</a></li>
<li><a href="/wiki/Male" id="w">Male</a> sex<sup id="_ref-Framingham1998_a" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup></li>
<li><a href="/wiki/Tobacco_smoking" id="w">Tobacco smoking</a></li>
<li><a href="/wiki/Hypercholesterolemia" id="w">Hypercholesterolemia</a> (more accurately <a href="/wiki/Hyperlipoproteinemia" id="w">hyperlipoproteinemia</a>, especially high <a href="/wiki/Low_density_lipoprotein" id="w">low density lipoprotein</a> and low <a href="/wiki/High_density_lipoprotein" id="w">high density lipoprotein</a>)</li>
<li><a href="/wiki/Hyperhomocysteinemia" id="w">Hyperhomocysteinemia</a> (high <a href="/wiki/Homocysteine" id="w">homocysteine</a>, a toxic blood <a href="/wiki/Amino_acid" id="w">amino acid</a> that is elevated when intakes of <a href="/wiki/Vitamins" id="w">vitamins</a> B2, B6, B12 and <a href="/wiki/Folic_acid" id="w">folic acid</a> are insufficient)</li>
<li><a href="/wiki/Diabetes_mellitus" id="w">Diabetes</a> (with or without <a href="/wiki/Insulin_resistance" id="w">insulin resistance</a>)</li>
<li><a href="/wiki/Hypertension" id="w">High blood pressure</a></li>
<li><a href="/wiki/Obesity" id="w">Obesity</a><sup id="_ref-Yusuf-2005_a" class="reference"><a href="#_note-Yusuf-2005" title="">[11]</a></sup> (defined by a <a href="/wiki/Body_mass_index" id="w">body mass index</a> of more than 30 kg/mÂ², or alternatively by waist circumference or <a href="/wiki/Waist-hip_ratio" id="w">waist-hip ratio</a>).</li></ul>
<p>Many of these risk factors are modifiable, so many heart attacks can be prevented by maintaining a healthier lifestyle. Physical activity, for example, is associated with a lower risk profile.<sup id="_ref-Jensen-1991_a" class="reference"><a href="#_note-Jensen-1991" title="">[12]</a></sup>  Non-modifiable risk factors include age, sex, and family history of an early heart attack (before the age of 60), which is thought of as reflecting a <a href="/wiki/Genetic_predisposition" id="w">genetic predisposition</a>.<sup id="_ref-Framingham1998_b" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup></p>
<p><a href="/wiki/Socioeconomics" id="w">Socioeconomic</a> factors such as a shorter <a href="/wiki/Education" id="w">education</a> and lower <a href="/wiki/Income" id="w">income</a> (particularly in women), and <a href="/wiki/Cohabitation" id="w">living with a partner</a> may also contribute to the risk of MI.<sup id="_ref-Nyboe-1989_a" class="reference"><a href="#_note-Nyboe-1989" title="">[13]</a></sup>  To understand epidemiological study results, it&#39;s important to note that many factors associated with MI mediate their risk via other factors. For example, the effect of education is partially based on its effect on income and <a href="/wiki/Marital_status" id="w">marital status</a>.<sup id="_ref-Nyboe-1989_b" class="reference"><a href="#_note-Nyboe-1989" title="">[13]</a></sup></p>
<p>Women who use <a href="/wiki/Combined_oral_contraceptive_pill" id="w">combined oral contraceptive pills</a> have a modestly increased risk of myocardial infarction, especially in the presence of other risk factors, such as smoking.<sup id="_ref-Khader-2003_a" class="reference"><a href="#_note-Khader-2003" title="">[14]</a></sup></p>
<p>Inflammation is known to be an important step in the process of <a href="/wiki/Atheroma" id="w">atherosclerotic plaque</a> formation.<sup id="_ref-Wilson-2006_a" class="reference"><a href="#_note-Wilson-2006" title="">[15]</a></sup>  <a href="/wiki/C-reactive_protein" id="w">C-reactive protein</a> (CRP) is a sensitive but non-specific <a href="/wiki/Biomarker_(medicine)" id="w">marker</a> for <a href="/wiki/Inflammation" id="w">inflammation</a>. Elevated CRP blood levels, especially measured with high sensitivity assays, can predict the risk of MI, as well as <a href="/wiki/Stroke" id="w">stroke</a> and development of diabetes.<sup id="_ref-Wilson-2006_b" class="reference"><a href="#_note-Wilson-2006" title="">[15]</a></sup> Moreover, some drugs for MI might also reduce CRP levels.<sup id="_ref-Wilson-2006_c" class="reference"><a href="#_note-Wilson-2006" title="">[15]</a></sup> The use of high sensitivity CRP assays as a means of <a href="/wiki/Screening_(medicine)" id="w">screening</a> the general population is advised against, but it may be used optionally at the physician&#39;s discretion, in patients who already present with other risk factors or known <a href="/wiki/Coronary_artery_disease" id="w">coronary artery disease</a>.<sup id="_ref-Pearson-2003_a" class="reference"><a href="#_note-Pearson-2003" title="">[16]</a></sup>  Whether CRP plays a direct role in atherosclerosis remains uncertain.<sup id="_ref-Wilson-2006_d" class="reference"><a href="#_note-Wilson-2006" title="">[15]</a></sup></p>
<p>Inflammation in <a href="/wiki/Periodontium" id="w">periodontal</a> disease may be linked coronary heart disease, and since <a href="/wiki/Periodontitis" id="w">periodontitis</a> is very common, this could have great consequences for <a href="/wiki/Public_health" id="w">public health</a>.<sup id="_ref-Janket-2003_a" class="reference"><a href="#_note-Janket-2003" title="">[17]</a></sup>  <a href="/wiki/Serology" id="w">Serological</a> studies measuring <a href="/wiki/Antibody" id="w">antibody</a> levels against typical periodontitis-causing <a href="/wiki/Bacteria" id="w">bacteria</a> found that such antibodies were more present in subjects with coronary heart disease.<sup id="_ref-Pihlstrom-2005_a" class="reference"><a href="#_note-Pihlstrom-2005" title="">[18]</a></sup>  Periodontitis tends to increase blood levels of CRP, <a href="/wiki/Fibrinogen" id="w">fibrinogen</a> and <a href="/wiki/Cytokines" id="w">cytokines</a>;<sup id="_ref-Scannapieco-2003_a" class="reference"><a href="#_note-Scannapieco-2003" title="">[19]</a></sup>  thus, periodontitis may mediate its effect on MI risk via other risk factors.<sup id="_ref-D'Aiuto-2006_a" class="reference"><a href="#_note-D'Aiuto-2006" title="">[20]</a></sup>  <a href="/wiki/Medical_research" id="w">Preclinical research</a> suggests that periodontal bacteria can promote aggregation of <a href="/wiki/Platelets" id="w">platelets</a> and promote the formation of <a href="/wiki/Foam_cell" id="w">foam cells</a>.<sup id="_ref-Lourbakos-2001_a" class="reference"><a href="#_note-Lourbakos-2001" title="">[21]</a></sup><sup id="_ref-Qi-2003_a" class="reference"><a href="#_note-Qi-2003" title="">[22]</a></sup>  A role for specific periodontal bacteria has been suggested but remains to be established.<sup id="_ref-Spahr-2006_a" class="reference"><a href="#_note-Spahr-2006" title="">[23]</a></sup></p>
<p><a href="/wiki/Baldness" id="w">Baldness</a>, <a href="/wiki/Grey_hair" id="w">hair greying</a>, a diagonal <a href="/wiki/Earlobe" id="w">earlobe crease</a><sup id="_ref-Lichstein-1974_a" class="reference"><a href="#_note-Lichstein-1974" title="">[24]</a></sup> and possibly other <a href="/wiki/Skin" id="w">skin</a> features are independent risk factors for MI. Their role remains controversial; a common denominator of these signs and the risk of MI is supposed, possibly genetic.<sup id="_ref-Miric-1998_a" class="reference"><a href="#_note-Miric-1998" title="">[25]</a></sup></p>
<a id="Pathophysiology" name="Pathophysiology"></a><h1>Pathophysiology</h1>

<p><div style="wigth:350px"><a class="internal" href="/wiki/Image:350px-Heart_attack_diagram.png" title="A myocardial infarction occurs when an [[atherosclerosis|atherosclerotic]] [[Atheroma|plaque]] slowly builds up in the inner lining of a [[coronary artery]] and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream."><img src="http://en.wikipedia.org/wiki/350px-Heart_attack_diagram.png" alt="A myocardial infarction occurs when an [[atherosclerosis|atherosclerotic]] [[Atheroma|plaque]] slowly builds up in the inner lining of a [[coronary artery]] and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream." title="A myocardial infarction occurs when an [[atherosclerosis|atherosclerotic]] [[Atheroma|plaque]] slowly builds up in the inner lining of a [[coronary artery]] and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream." class="location-right type-thumb" width="350px" />
</a>
<div class="thumbcaption">A myocardial infarction occurs when an <a href="/wiki/Atherosclerosis" id="w">atherosclerotic</a> <a href="/wiki/Atheroma" id="w">plaque</a> slowly builds up in the inner lining of a <a href="/wiki/Coronary_artery" id="w">coronary artery</a> and then suddenly ruptures, totally occluding the artery and preventing blood flow downstream.</div></div>
</p>
<p>{{main}}</p>
<p>Acute myocardial infarction is a type of <a href="/wiki/Acute__coronary_syndrome" id="w">acute  coronary syndrome</a>, which is most frequently (but not always) a manifestation of <a href="/wiki/Coronary_artery_disease" id="w">coronary artery disease</a>. The most common triggering event is the disruption of an <a href="/wiki/Atherosclerosis" id="w">atherosclerotic</a> <a href="/wiki/Atheroma" id="w">plaque</a> in an epicardial coronary artery, which leads to a clotting cascade, sometimes resulting in total occlusion of the artery. Atherosclerosis is the gradual buildup of <a href="/wiki/Cholesterol" id="w">cholesterol</a> and fibrous tissue in plaques in the wall of <a href="/wiki/Artery" id="w">arteries</a> (in this case, the <a href="/wiki/Coronary_artery" id="w">coronary arteries</a>), typically over decades. Blood stream column irregularities visible on angiographies reflect artery <a href="/wiki/Lumen" id="w">lumen</a> narrowing as a result of decades of advancing atherosclerosis. Plaques can become unstable, rupture, and additionally promote a <a href="/wiki/Thrombus" id="w">thrombus</a> (blood clot) that occludes the artery; this can occur in minutes. When a severe enough plaque rupture occurs in the coronary vasculature, it leads to myocardial infarction (necrosis of downstream myocardium).</p>
<p>If impaired blood flow to the heart lasts long enough, it triggers a process called the <a href="/wiki/Ischemic_cascade" id="w">ischemic cascade</a>; the heart cells die (chiefly through  <a href="/wiki/Necrosis" id="w">necrosis</a>) and do not grow back. A <a href="/wiki/Collagen" id="w">collagen</a> <a href="/wiki/Scar" id="w">scar</a> forms in its place. Recent studies indicate that another form of cell death called <a href="/wiki/Apoptosis" id="w">apoptosis</a> also plays a role in the process of tissue damage subsequent to myocardial infarction.<sup id="_ref-Krijnen-2002_a" class="reference"><a href="#_note-Krijnen-2002" title="">[26]</a></sup>  As a result, the patient&#39;s heart can be permanently damaged. This scar tissue also puts the patient at risk for potentially life threatening arrhythmias.</p>
<p>Injured heart tissue conducts electrical impulses more slowly than normal heart tissue. The difference in conduction velocity between injured and uninjured tissue can trigger <a href="/wiki/Cardiac_arrhythmia#Re-entry" id="w">re-entry</a> or a feedback loop that is believed to be the cause of many lethal arrhythmias. The most serious of these arrhythmias is <a href="/wiki/Ventricular_fibrillation" id="w">ventricular fibrillation</a> (<i>V-Fib</i>/VF), an extremely fast and chaotic heart rhythm that is the leading cause of sudden cardiac death. Another life threatening arrhythmia is <a href="/wiki/Ventricular_tachycardia" id="w">ventricular tachycardia</a> (<i>V-Tach</i>/VT), which may or may not cause sudden cardiac death. However, ventricular tachycardia usually results in rapid heart rates that prevent the heart from pumping blood effectively. <a href="/wiki/Cardiac_output" id="w">Cardiac output</a> and <a href="/wiki/Blood_pressure" id="w">blood pressure</a> may fall to dangerous levels, which is particularly bad for the patient experiencing acute myocardial infarction.</p>
<p>The <a href="/wiki/Defibrillator" id="w">cardiac defibrillator</a> is a device that was specifically designed to terminate these potentially fatal arrhythmias. The device works by delivering an electrical shock to the patient in order to depolarize a critical mass of the heart muscle, in effect &#34;<a href="/wiki/Reboot" id="w">rebooting</a>&#34; the heart. This therapy is time dependent, and the odds of successful defibrillation decline rapidly after the onset of cardiopulmonary arrest.</p>
<a id="Triggers" name="Triggers"></a><h1>Triggers</h1>
<p>Heart attack rates are higher in association with intense exertion, be it <a href="/wiki/Stress_(psychology)" id="w">psychological stress</a> or physical exertion, especially if the exertion is more intense than the individual usually performs.<sup id="_ref-Framingham1998_c" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup> Quantitatively, the period of intense exercise and subsequent recovery is associated with about a 6-fold higher myocardial infarction rate (compared with other more relaxed time frames) for people who are physically very fit.<sup id="_ref-Framingham1998_d" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup> For those in poor physical condition, the rate differential is over 35-fold higher.<sup id="_ref-Framingham1998_e" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup> One observed mechanism for this phenomenon is the increased arterial pulse pressure stretching and relaxation of arteries with each heart beat which, as has been observed with <a href="/wiki/Intravascular_ultrasound" id="w">intravascular ultrasound</a>, increases mechanical &#34;shear stress&#34; on <a href="/wiki/Atheroma" id="w">atheromas</a> and the likelihood of plaque rupture.<sup id="_ref-Framingham1998_f" class="reference"><a href="#_note-Framingham1998" title="">[10]</a></sup></p>
<p>Acute severe infection, such as <a href="/wiki/Pneumonia" id="w">pneumonia</a>, can trigger myocardial infarction. A more controversial link is that between <i><a href="/wiki/Chlamydophila_pneumoniae" id="w">Chlamydophila pneumoniae</a></i> infection and atherosclerosis.<sup id="_ref-Saikku-1992_a" class="reference"><a href="#_note-Saikku-1992" title="">[27]</a></sup> While this intracellular organism has been demonstrated in atherosclerotic plaques, evidence is inconclusive as to whether it can be considered a causative factor.<sup id="_ref-Saikku-1992_b" class="reference"><a href="#_note-Saikku-1992" title="">[27]</a></sup> Treatment with antibiotics in patients with proven atherosclerosis has not demonstrated a decreased risk of heart attacks or other coronary vascular diseases.<sup id="_ref-Andraws-2005_a" class="reference"><a href="#_note-Andraws-2005" title="">[28]</a></sup></p>
<a id="Classification" name="Classification"></a><h1>Classification</h1>
<p><div style="wigth:300px"><a class="internal" href="/wiki/Image:300px-ACS_scheme.jpg" title="Classification of [[acute coronary syndrome]]s.&#60;ref name=&#34;Alpert-2000&#34;&#62;{{cite journal}}&#60;/ref&#62;"><img src="http://en.wikipedia.org/wiki/300px-ACS_scheme.jpg" alt="Classification of [[acute coronary syndrome]]s.&#60;ref name=&#34;Alpert-2000&#34;&#62;{{cite journal}}&#60;/ref&#62;" title="Classification of [[acute coronary syndrome]]s.&#60;ref name=&#34;Alpert-2000&#34;&#62;{{cite journal}}&#60;/ref&#62;" class="location-right type-thumb" width="300px" />
</a>
<div class="thumbcaption">Classification of <a href="/wiki/Acute_coronary_syndrome" id="w">acute coronary syndromes</a>.<sup id="_ref-Alpert-2000_a" class="reference"><a href="#_note-Alpert-2000" title="">[29]</a></sup></div></div>
</p>
<p>Acute myocardial infarction is a type of <a href="/wiki/Acute_coronary_syndrome" id="w">acute coronary syndrome</a>, which is most frequently (but not always) a manifestation of <a href="/wiki/Coronary_artery_disease" id="w">coronary artery disease</a>. The acute coronary syndromes include ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), and <a href="/wiki/Unstable_angina" id="w">unstable angina</a> (UA).</p>
<p>Depending on the location of the obstruction in the <a href="/wiki/Coronary_circulation" id="w">coronary circulation</a>, different zones of the heart can become injured. Using the <a href="/wiki/Anatomical_terms_of_location" id="w">anatomical terms of location</a>, one can describe anterior, inferior, lateral, apical and septal infarctions (and combinations, such as anteroinferior, anterolateral, and so on).<sup id="_ref-MedicalDictionary_a" class="reference"><a href="#_note-MedicalDictionary" title="">[30]</a></sup>  For example, an occlusion of the <a href="/wiki/Left_anterior_descending_coronary_artery" id="w">left anterior descending coronary artery</a> will result in an anterior wall myocardial infarct.<sup id="_ref-rubin525_a" class="reference"><a href="#_note-rubin525" title="">[31]</a></sup></p>
<p>Another distinction is whether a MI is subendocardial, affecting only the inner third to one half of the heart muscle, or transmural, damaging (almost) the entire wall of the heart.<sup id="_ref-rubin's-p545_a" class="reference"><a href="#_note-rubin's-p545" title="">[32]</a></sup> The inner part of the heart muscle is more vulnerable to oxygen shortage, because the coronary arteries run inward from the <a href="/wiki/Epicardium" id="w">epicardium</a> to the <a href="/wiki/Endocardium" id="w">endocardium</a>, and because the blood flow through the heart muscle is hindered by the <a href="/wiki/Systole_(medicine)" id="w">heart contraction</a>.<sup id="_ref-rubin525_b" class="reference"><a href="#_note-rubin525" title="">[31]</a></sup></p>
<p>The phrases transmural and subendocardial infarction used to be considered synonymous with Q-wave and non-Q-wave myocardial infarction respectively, based on the presence or absence of Q waves on the ECG. It has since been shown that there is no clear <a href="/wiki/Correlation" id="w">correlation</a> between the presence of Q waves with a transmural infarction and the absence of Q waves with a subendocardial infarction,<sup id="_ref-Moon-2004_a" class="reference"><a href="#_note-Moon-2004" title="">[33]</a></sup> but Q waves are associated with larger infarctions, while the lack of Q waves is associated with smaller infarctions. The presence or absence of Q-waves also has clinical importance,<sup id="_ref-Yang-2004_a" class="reference"><a href="#_note-Yang-2004" title="">[34]</a></sup> with improved outcomes associated with a lack of Q waves.<sup id="_ref-Goodman-1998_a" class="reference"><a href="#_note-Goodman-1998" title="">[35]</a></sup></p>
<p>The phrase &#34;massive attack&#34; is not a recognized medical term.</p>
<a id="Symptoms" name="Symptoms"></a><h1>Symptoms</h1>
<p><div style="wigth:150px"><a class="internal" href="/wiki/Image:150px-AMI_pain_front.png" title="Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest)."><img src="http://en.wikipedia.org/wiki/150px-AMI_pain_front.png" alt="Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest)." title="Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest)." class="location-right type-thumb" width="150px" />
</a>
<div class="thumbcaption">Rough diagram of pain zones in myocardial infarction (dark red = most typical area, light red = other possible areas, view of the chest).</div></div>

<div style="wigth:150px"><a class="internal" href="/wiki/Image:150px-AMI_pain_back.png" title="Back view."><img src="http://en.wikipedia.org/wiki/150px-AMI_pain_back.png" alt="Back view." title="Back view." class="location-right type-thumb" width="150px" />
</a>
<div class="thumbcaption">Back view.</div></div>
</p>
<p>The onset of symptoms in myocardial infarction (MI) is usually gradual, over several minutes, and rarely instantaneous.<sup id="_ref-warningsigns_a" class="reference"><a href="#_note-warningsigns" title="">[36]</a></sup> <a href="/wiki/Chest_pain" id="w">Chest pain</a> is the most common symptom of acute myocardial infarction and is often described as a sensation of tightness, pressure, or squeezing. Chest pain due to <a href="/wiki/Ischemia" id="w">ischemia</a> (a lack of blood and hence oxygen supply) of the heart muscle is termed <a href="/wiki/Angina_pectoris" id="w">angina pectoris</a>. Pain radiates most often to the left <a href="/wiki/Arm" id="w">arm</a>, but may also radiate to the lower <a href="/wiki/Jaw" id="w">jaw</a>, <a href="/wiki/Neck" id="w">neck</a>, right arm, <a href="/wiki/Human_back" id="w">back</a>, and <a href="/wiki/Epigastrium" id="w">epigastrium</a>, where it may mimic <a href="/wiki/Heartburn" id="w">heartburn</a>. Any group of symptoms compatible with a sudden interruption of the blood flow to the heart are called an <a href="/wiki/Acute_coronary_syndrome" id="w">acute coronary syndrome</a>.<sup id="_ref-ACS_a" class="reference"><a href="#_note-ACS" title="">[37]</a></sup> Other conditions such as <a href="/wiki/Aortic_dissection" id="w">aortic dissection</a> or <a href="/wiki/Pulmonary_embolism" id="w">pulmonary embolism</a> may present with chest pain and must be considered in the <a href="/wiki/Differential_diagnosis" id="w">differential diagnosis</a>.</p>
<p>Shortness of breath (<a href="/wiki/Dyspnea" id="w">dyspnea</a>) occurs when the damage to the heart limits the <a href="/wiki/Cardiac_output" id="w">output</a> of the <a href="/wiki/Left_ventricle" id="w">left ventricle</a>, causing <a href="/wiki/Left_ventricular_failure" id="w">left ventricular failure</a> and consequent <a href="/wiki/Pulmonary_edema" id="w">pulmonary edema</a>.  Other symptoms include <a href="/wiki/Diaphoresis" id="w">diaphoresis</a> (an excessive form of <a href="/wiki/Sweating" id="w">sweating</a>), weakness, <a href="/wiki/Light-headedness" id="w">light-headedness</a>, <a href="/wiki/Nausea" id="w">nausea</a>, <a href="/wiki/Vomiting" id="w">vomiting</a>, and <a href="/wiki/Palpitation" id="w">palpitations</a>. <a href="/wiki/Unconsciousness" id="w">Loss of consciousness</a> and even <a href="/wiki/Sudden_cardiac_death" id="w">sudden death</a> can occur in myocardial infarctions.</p>
<p>Women often experience markedly different symptoms than men. The most common symptoms of MI in women include dyspnea, weakness, and <a href="/wiki/Fatigue_(physical)" id="w">fatigue</a>. Fatigue, sleep disturbances, and <a href="/wiki/Dyspnea" id="w">dyspnea</a> have been reported as frequently occurring symptoms which may manifest as long as one month before the actual clinically manifested ischemic event. In women, <a href="/wiki/Chest_pain" id="w">chest pain</a> may be less predictive of coronary <a href="/wiki/Ischemia" id="w">ischemia</a> than in men.<sup id="_ref-McSweeney_a" class="reference"><a href="#_note-McSweeney" title="">[38]</a></sup></p>
<p>Approximately half of all MI patients have experienced warning symptoms such as chest pain prior to the infarction.<sup id="_ref-MedicineNet_a" class="reference"><a href="#_note-MedicineNet" title="">[39]</a></sup></p>
<p>Approximately one fourth of all myocardial infarctions are silent, without chest pain or other symptoms.<sup id="_ref-Kannel-1986_a" class="reference"><a href="#_note-Kannel-1986" title="">[40]</a></sup>  These cases can be discovered later on electrocardiograms or at autopsy without a prior history of related complaints. A silent course is more common in the <a href="/wiki/Elderly" id="w">elderly</a>, in  patients with <a href="/wiki/Diabetes_mellitus" id="w">diabetes mellitus</a><sup id="_ref-Diabetologica2004-David_a" class="reference"><a href="#_note-Diabetologica2004-David" title="">[41]</a></sup> and after <a href="/wiki/Heart_transplantation" id="w">heart transplantation</a>, probably because the <a href="/wiki/Organ_donation" id="w">donor</a> heart is not connected to nerves of the host.<sup id="_ref-rubin's_a" class="reference"><a href="#_note-rubin's" title="">[42]</a></sup> In diabetics, differences in <a href="/wiki/Pain_threshold" id="w">pain threshold</a>, <a href="/wiki/Autonomic_neuropathy" id="w">autonomic neuropathy</a>, and <a href="/wiki/Psychology" id="w">psychological</a> factors have been cited as possible explanations for the lack of symptoms.<sup id="_ref-Diabetologica2004-David_b" class="reference"><a href="#_note-Diabetologica2004-David" title="">[41]</a></sup></p>
<a id="Diagnosis" name="Diagnosis"></a><h1>Diagnosis</h1>
<p>The diagnosis of myocardial infarction is made by integrating the history of the presenting illness and physical examination with <a href="/wiki/Electrocardiogram" id="w">electrocardiogram</a> findings and <a href="/wiki/Cardiac_marker" id="w">cardiac markers</a> (<a href="/wiki/Blood_test" id="w">blood tests</a> for <a href="/wiki/Cardiac_muscle" id="w">heart muscle</a> <a href="/wiki/Cell_(biology)" id="w">cell</a> damage).<sup id="_ref-GPnotebook_MI_a" class="reference"><a href="#_note-GPnotebook_MI" title="">[43]</a></sup> A <a href="/wiki/Coronary_catheterization" id="w">coronary angiogram</a> allows to visualize narrowings or obstructions on the heart vessels, and therapeutic measures can follow immediately. At <a href="/wiki/Autopsy" id="w">autopsy</a>, a <a href="/wiki/Pathologist" id="w">pathologist</a> can diagnose a myocardial infarction based on <a href="/wiki/Anatomical_pathology" id="w">anatomopathological</a> findings.  </p>
<p>A <a href="/wiki/Chest_radiograph" id="w">chest radiograph</a> and routine blood tests may indicate complications or precipitating causes and are often performed on admittance to an <a href="/wiki/Emergency_department" id="w">emergency department</a>. New regional wall motion abnormalities on an <a href="/wiki/Medical_ultrasonography" id="w">echocardiogram</a> are also suggestive of a myocardial infarction and are sometimes performed in equivocal cases.<sup id="_ref-eMedicineEMERG_a" class="reference"><a href="#_note-eMedicineEMERG" title="">[44]</a></sup> <a href="/wiki/Technetium" id="w">Technetium</a> and <a href="/wiki/Thallium" id="w">thallium</a> can be used in <a href="/wiki/Nuclear_medicine" id="w">nuclear medicine</a> to visualize areas of reduced blood flow and tissue viability, respectively.<sup id="_ref-eMedicineEMERG_b" class="reference"><a href="#_note-eMedicineEMERG" title="">[44]</a></sup><sup id="_ref-heartscanpage_a" class="reference"><a href="#_note-heartscanpage" title="">[45]</a></sup> Technetium is used in a <a href="/wiki/MUGA_scan" id="w">MUGA scan</a>.</p>
<a id="Diagnostic_criteria" name="Diagnostic_criteria"></a><h2>Diagnostic criteria</h2>
<p>WHO criteria<sup id="_ref-Gillum_a" class="reference"><a href="#_note-Gillum" title="">[46]</a></sup> have classically been used to diagnose MI; a patient is diagnosed with myocardial infarction if two (probable) or three (definite) of the following criteria are satisfied:
</p>
<ol>
<li>Clinical history of ischaemic type chest pain lasting for more than 20 minutes</li>
<li>Changes in serial ECG tracings</li>
<li>Rise and fall of serum cardiac biomarkers such as <a href="/wiki/Creatine_kinase" id="w">creatine kinase</a>, <a href="/wiki/Troponin" id="w">troponin</a> I, and <a href="/wiki/Lactate_dehydrogenase" id="w">lactate dehydrogenase</a> <a href="/wiki/Isozyme" id="w">isozymes</a> specific for the heart.</li></ol>
<p>The WHO criteria were refined in 2000 to give more prominence to cardiac biomarkers.<sup id="_ref-Alpert-2000_b" class="reference"><a href="#_note-Alpert-2000" title="">[29]</a></sup> According to the new guidelines, a cardiac <a href="/wiki/Troponin" id="w">troponin</a> rise accompanied by either typical symptoms, pathological Q waves, ST elevation or depression or coronary intervention are diagnostic of MI.</p>
<a id="Physical_examination" name="Physical_examination"></a><h2>Physical examination</h2>
<p>The general appearance of patients may vary according to the experienced symptoms; the patient may be comfortable, or restless and in severe distress with an increased <a href="/wiki/Respiratory_rate" id="w">respiratory rate</a>. A cool and <a href="/wiki/Pallor" id="w">pale skin</a> is common and points to <a href="/wiki/Vasoconstriction" id="w">vasoconstriction</a>. Some patients have low-grade fever (38â39 Â°C). <a href="/wiki/Blood_pressure" id="w">Blood pressure</a> may be elevated or decreased, and the <a href="/wiki/Pulse" id="w">pulse</a> can be become <a href="/wiki/Cardiac_arrhythmia" id="w">irregular</a>.<sup id="_ref-emedicine_a" class="reference"><a href="#_note-emedicine" title="">[47]</a></sup><sup id="_ref-harrisons-p1444_a" class="reference"><a href="#_note-harrisons-p1444" title="">[48]</a></sup></p>
<p>If heart failure ensues, elevated <a href="/wiki/Jugular_venous_pressure" id="w">jugular venous pressure</a> and <a href="/wiki/Hepatojugular_reflux" id="w">hepatojugular reflux</a>, or swelling of the legs due to peripheral <a href="/wiki/Edema" id="w">edema</a> may be found on inspection. Rarely, a cardiac bulge with a pace different from the pulse rhythm can be felt on <a href="/wiki/Precordial_examination" id="w">precordial examination</a>. Various abnormalities can be found on <a href="/wiki/Auscultation" id="w">auscultation</a>, such as a third and fourth <a href="/wiki/Heart_sounds" id="w">heart sound</a>, <a href="/wiki/Heart_murmur" id="w">systolic murmurs</a>, paradoxical splitting of the second heart sound, a <a href="/wiki/Pericardium" id="w">pericardial</a> friction rub and <a href="/wiki/Rales" id="w">rales</a> over the lung.<sup id="_ref-emedicine_b" class="reference"><a href="#_note-emedicine" title="">[47]</a></sup><sup id="_ref-harrisons-p1450_a" class="reference"><a href="#_note-harrisons-p1450" title="">[49]</a></sup></p>
<p><div style="wigth:325px"><a class="internal" href="/wiki/Image:325px-ECG_001.jpg" title="12-lead [[electrocardiogram]] (ECG) showing acute inferior ST segment elevation MI (STEMI). Note the ST segment elevation in leads II, III, and aVF along with reciprocal ST segment depression in leads I and aVL."><img src="http://en.wikipedia.org/wiki/325px-ECG_001.jpg" alt="12-lead [[electrocardiogram]] (ECG) showing acute inferior ST segment elevation MI (STEMI). Note the ST segment elevation in leads II, III, and aVF along with reciprocal ST segment depression in leads I and aVL." title="12-lead [[electrocardiogram]] (ECG) showing acute inferior ST segment elevation MI (STEMI). Note the ST segment elevation in leads II, III, and aVF along with reciprocal ST segment depression in leads I and aVL." class="location-none type-thumb" width="325px" />
</a>
<div class="thumbcaption">12-lead <a href="/wiki/Electrocardiogram" id="w">electrocardiogram</a> (ECG) showing acute inferior ST segment elevation MI (STEMI). Note the ST segment elevation in leads II, III, and aVF along with reciprocal ST segment depression in leads I and aVL.</div></div>
</p>
<a id="Electrocardiogram" name="Electrocardiogram"></a><h2>Electrocardiogram</h2>
<p>{{main}}
The primary purpose of the <a href="/wiki/Electrocardiogram" id="w">electrocardiogram</a> is to detect <a href="/wiki/Ischemia" id="w">ischemia</a> or acute coronary injury in broad, symptomatic <a href="/wiki/Emergency_department" id="w">emergency department</a> populations. However, the standard 12 lead <a href="/wiki/Electrocardiogram" id="w">ECG</a> has several limitations. An <a href="/wiki/Electrocardiogram" id="w">ECG</a> represents a brief sample in time. Because unstable ischemic syndromes have rapidly changing supply versus demand characteristics, a single <a href="/wiki/Electrocardiogram" id="w">ECG</a> may not accurately represent the entire picture.<sup id="_ref-Cannon_175_a" class="reference"><a href="#_note-Cannon_175" title="">[50]</a></sup> It is therefore desirable to obtain serial 12 lead <a href="/wiki/ECG" id="w">ECGs</a>, particularly if the first <a href="/wiki/Electrocardiogram" id="w">ECG</a> is obtained during a pain-free episode. Alternatively, many <a href="/wiki/Emergency_department" id="w">emergency departments</a> and <a href="/wiki/Chest_pain_center" id="w">chest pain centers</a> use computers capable of continuous ST segment monitoring.<sup id="_ref-NHAAP_1997_a" class="reference"><a href="#_note-NHAAP_1997" title="">[51]</a></sup> It should also be appreciated that the standard 12 lead <a href="/wiki/Electrocardiogram" id="w">ECG</a> does not directly examine the <a href="/wiki/Right_ventricle" id="w">right ventricle</a>, and does a relatively poor job of examining the posterior basal and lateral walls of the <a href="/wiki/Left_ventricle" id="w">left ventricle</a>. In particular, acute myocardial infarction in the distribution of the circumflex artery is likely to produce a nondiagnostic <a href="/wiki/Electrocardiogram" id="w">ECG</a>.<sup id="_ref-Cannon_175_b" class="reference"><a href="#_note-Cannon_175" title="">[50]</a></sup> The use of non-standard <a href="/wiki/Electrocardiogram" id="w">ECG</a> leads like right-sided lead V4R and posterior leads V7, V8, and V9 may improve sensitivity for right ventricular and posterior myocardial infarction. In spite of these limitations, the 12 lead <a href="/wiki/Electrocardiogram" id="w">ECG</a> stands at the center of risk stratification for the patient with suspected acute myocardial infarction. Mistakes in interpretation are relatively common, and the failure to identify high risk features has a negative effect on the quality of patient care.<sup id="_ref-EDQMI_2006_a" class="reference"><a href="#_note-EDQMI_2006" title="">[52]</a></sup>
The 12 lead ECG is used to classify patients into one of three groups:
</p><dl><dd>1. those with ST segment elevation or new bundle branch block (suspicious for acute injury and a possible candidate for acute reperfusion therapy with <a href="/wiki/Thrombolysis" id="w">thrombolytics</a> or primary <a href="/wiki/Percutaneous_coronary_intervention" id="w">PCI</a>),</dd></dl><dl><dd>2. those with ST segment depression or T wave inversion (suspicious for ischemia), and</dd></dl><dl><dd>3. those with a so-called non-diagnostic or normal ECG.<sup id="_ref-ECC_2005_ACS_a" class="reference"><a href="#_note-ECC_2005_ACS" title="">[53]</a></sup></dd></dl>
<p>A normal ECG does not rule out acute myocardial infarction. Sometimes the earliest presentation of acute myocardial infarction is the hyperacute T wave, which is treated the same as ST segment elevation.<sup id="_ref-Hyperacute2002_a" class="reference"><a href="#_note-Hyperacute2002" title="">[54]</a></sup> In practice this is rarely seen, because it only exists for 2-30 minutes after the onset of infarction.<sup id="_ref-ACS_Clin_NA_a" class="reference"><a href="#_note-ACS_Clin_NA" title="">[55]</a></sup> Hyperacute T waves need to be distinguished from the peaked T waves associated with <a href="/wiki/Hyperkalemia" id="w">hyperkalemia</a>.<sup id="_ref-ECG_Noncardiac_a" class="reference"><a href="#_note-ECG_Noncardiac" title="">[56]</a></sup> The current guidelines for the ECG diagnosis of acute myocardial infarction require at least 1 mm (0.1 mV) of ST segment elevation in 2 or more anatomically contiguous leads.<sup id="_ref-ECC_2005_ACS_b" class="reference"><a href="#_note-ECC_2005_ACS" title="">[53]</a></sup> This criterion is problematic, however, as acute myocardial infarction is not the most common cause of ST segment elevation in <a href="/wiki/Chest_pain" id="w">chest pain</a> patients.<sup id="_ref-Cause_ST_ED_a" class="reference"><a href="#_note-Cause_ST_ED" title="">[57]</a></sup> In addition, over 90% of healthy men have at least 1 mm (0.1 mV) of ST segment elevation in at least one precordial lead.<sup id="_ref-ST_Other_MI_a" class="reference"><a href="#_note-ST_Other_MI" title="">[58]</a></sup> The clinician must therefore be well versed in recognizing the so-called ECG mimics of acute myocardial infarction, which include <a href="/wiki/Left_ventricular_hypertrophy" id="w">left ventricular hypertrophy</a>, <a href="/wiki/Left_bundle_branch_block" id="w">left bundle branch block</a>, <a href="/wiki/Artificial_pacemaker" id="w">paced rhythm</a>, benign early repolarization, <a href="/wiki/Pericarditis" id="w">pericarditis</a>, <a href="/wiki/Hyperkalemia" id="w">hyperkalemia</a>, and ventricular aneurysm.<sup id="_ref-ECG_Confound_a" class="reference"><a href="#_note-ECG_Confound" title="">[59]</a></sup><sup id="_ref-STE_AMI_non-AMI_a" class="reference"><a href="#_note-STE_AMI_non-AMI" title="">[60]</a></sup><sup id="_ref-ST_Other_MI_b" class="reference"><a href="#_note-ST_Other_MI" title="">[58]</a></sup></p>
<p><a href="/wiki/Left_bundle_branch_block" id="w">Left bundle branch block</a> and <a href="/wiki/Artificial_pacemaker" id="w">pacing</a> can interfere with the electrocardiographic diagnosis of acute myocadial infarction. The GUSTO investigators Sgarbossa et al. developed a set of criteria for identifying acute myocardial infarction in the presence of left bundle branch block and paced rhythm. They include concordant ST segment elevation &#62; 1 mm (0.1 mV), discordant ST segment elevation &#62; 5 mm (0.5 mV), and concordant ST segment depression in the left precordial leads.<sup id="_ref-NEJM_Sgarbossa_a" class="reference"><a href="#_note-NEJM_Sgarbossa" title="">[61]</a></sup> The presence of reciprocal changes on the 12 lead ECG may help distinguish true acute myocardial infarction from the mimics of acute myocardial infarction. The contour of the ST segment may also be helpful, with a straight or upwardly convex (non-concave) ST segment favoring the diagnosis of acute myocardial infarction.<sup id="_ref-Contour_ST_a" class="reference"><a href="#_note-Contour_ST" title="">[62]</a></sup></p>
<p>The constellation of leads with ST segment elevation enables the clinician to identify what area of the heart is injured, which in turn helps predict the so-called culprit artery.</p>

<div style="page-break-inside:	avoid;">
<table align="center" border="1" cellpadding="5" cellspacing="0" class="wikitable">
<tr>
<th>Wall Affected</th>
<th>Leads Showing ST Segment Elevation</th>
<th>Leads Showing Reciprocal ST Segment Depression</th>
<th>Suspected Culprit Artery</th></tr>
<tr>
<td>Septal</td>
<td>V<sub>1</sub>, V<sub>2</sub></td>
<td>None</td>
<td><a href="/wiki/Anterior_interventricular_branch_of_left_coronary_artery" id="w">Left Anterior Descending (LAD)</a></td></tr>
<tr>
<td>Anterior</td>
<td>V<sub>3</sub>, V<sub>4</sub></td>
<td>None</td>
<td><a href="/wiki/Anterior_interventricular_branch_of_left_coronary_artery" id="w">Left Anterior Descending (LAD)</a></td></tr>
<tr>
<td>Anteroseptal</td>
<td>V<sub>1</sub>, V<sub>2</sub>, V<sub>3</sub>, V<sub>4</sub></td>
<td>None</td>
<td><a href="/wiki/Anterior_interventricular_branch_of_left_coronary_artery" id="w">Left Anterior Descending (LAD)</a></td></tr>
<tr>
<td>Anterolateral</td>
<td>V<sub>3</sub>, V<sub>4</sub>, V<sub>5</sub>, V<sub>6</sub>, I, aVL</td>
<td>II, III, aVF</td>
<td><a href="/wiki/Anterior_interventricular_branch_of_left_coronary_artery" id="w">Left Anterior Descending (LAD)</a>, <a href="/wiki/Circumflex_branch_of_left_coronary_artery" id="w">Circumflex (LCX)</a>, or <a href="/wiki/Left_marginal_artery" id="w">Obtuse Marginal</a></td></tr>
<tr>
<td>Extensive anterior (Sometimes called Anteroseptal with Lateral extension)</td>
<td>V<sub>1</sub>,V<sub>2</sub>,V<sub>3</sub>, V<sub>4</sub>, V<sub>5</sub>, V<sub>6</sub>, I, aVL</td>
<td>II, III, aVF</td>
<td><a href="/wiki/Left_coronary_artery" id="w">Left main coronary artery (LCA)</a></td></tr>
<tr>
<td><a href="/wiki/Diaphragmatic_surface_of_heart" id="w">Inferior</a></td>
<td>II, III, aVF</td>
<td>I, aVL</td>
<td><a href="/wiki/Right_coronary_artery" id="w">Right Coronary Artery (RCA) or Circumflex (LCX)</a></td></tr>
<tr>
<td>Lateral</td>
<td>I, aVL, V<sub>5</sub>, V<sub>6</sub></td>
<td>II, III, aVF</td>
<td><a href="/wiki/Circumflex_branch_of_left_coronary_artery" id="w">Circumflex (LCX)</a> or <a href="/wiki/Left_marginal_artery" id="w">Obtuse Marginal</a></td></tr>
<tr>
<td>Posterior (Usually associated with Inferior or Lateral but can be isolated)</td>
<td>V<sub>7</sub>, V<sub>8</sub>, V<sub>9</sub></td>
<td>V<sub>1</sub>,V<sub>2</sub>,V<sub>3</sub>, V<sub>4</sub></td>
<td><a href="/wiki/Posterior_descending_artery" id="w">Posterior Descending (PDA)</a> (branch of the <a href="/wiki/Right_coronary_artery" id="w">RCA</a> or <a href="/wiki/Circumflex_artery" id="w">Circumflex (LCX)</a>)</td></tr>
<tr>
<td><a href="/wiki/Right_ventricle" id="w">Right ventricular</a> (Usually associated with Inferior)</td>
<td>II, III, aVF, V<sub>1</sub>, V<sub>4</sub>R</td>
<td>I, aVL</td>
<td><a href="/wiki/Right_coronary_artery" id="w">Right Coronary Artery (RCA)</a></td></tr></table></div>

<p>As the myocardial infarction evolves, there may be loss of R wave height and development of pathological Q waves. T wave inversion may persist for months or even permanently following acute myocardial infarction.<sup id="_ref-63" class="reference"><a href="#_note-63" title="">[63]</a></sup> Typically, however, the T wave recovers, leaving a pathological Q wave as the only remaining evidence that an acute myocardial infarction has occurred.</p>
<a id="Cardiac_markers" name="Cardiac_markers"></a><h2>Cardiac markers</h2>
<p>{{main}}</p>
<p>Cardiac markers or cardiac enzymes are proteins from cardiac tissue found in the blood. These proteins are released into the bloodstream when damage to the heart occurs, as in the case of a myocardial infarction. Until the 1980s, the enzymes <a href="/wiki/Aspartate_transaminase" id="w">SGOT</a> and <a href="/wiki/Lactate_dehydrogenase" id="w">LDH</a> were used to assess cardiac injury. Then it was found that disproportional elevation of the <i>MB</i> subtype of the enzyme <a href="/wiki/Creatine_kinase" id="w">creatine kinase</a> (CK) was very specific for myocardial injury. Current guidelines are generally in favor of <a href="/wiki/Troponin" id="w">troponin</a> sub-units I or T, which are very specific for the heart muscle and are thought to rise before permanent injury develops.<sup id="_ref-64" class="reference"><a href="#_note-64" title="">[64]</a></sup> Elevated troponins in the setting of chest pain may accurately predict a high likelihood of a myocardial infarction in the near future.<sup id="_ref-65" class="reference"><a href="#_note-65" title="">[65]</a></sup></p>
<p>The diagnosis of myocardial infarction requires two out of three components (history, ECG, and enzymes).  When damage to the heart occurs, levels of cardiac markers rise over time, which is why <a href="/wiki/Blood_test" id="w">blood tests</a> for them are taken over a 24 hour period. Because these enzyme levels are not elevated immediately following a heart attack, patients presenting with chest pain are generally treated with the assumption that a myocardial infarction has occurred and then evaluated for a more precise diagnosis.<sup id="_ref-Braunwald-2002_a" class="reference"><a href="#_note-Braunwald-2002" title="">[66]</a></sup></p>
<a id="Angiography" name="Angiography"></a><h2>Angiography</h2>
<p><div style="wigth:250px"><a class="internal" href="/wiki/Image:250px-Ha1.jpg" title="[[Angiogram]] of the coronary arteries."><img src="http://en.wikipedia.org/wiki/250px-Ha1.jpg" alt="[[Angiogram]] of the coronary arteries." title="[[Angiogram]] of the coronary arteries." class="location-none type-thumb" width="250px" />
</a>
<div class="thumbcaption"><a href="/wiki/Angiogram" id="w">Angiogram</a> of the coronary arteries.</div></div>

{{main}}</p>
<p>In difficult cases or in situations where intervention to restore blood flow is appropriate, coronary <a href="/wiki/Angiography" id="w">angiography</a> can be performed. A <a href="/wiki/Catheter" id="w">catheter</a> is inserted into an artery (usually the <a href="/wiki/Femoral_artery" id="w">femoral artery</a>) and pushed to the vessels supplying the heart. Obstructed or narrowed arteries can be identified, and <a href="/wiki/Angioplasty" id="w">angioplasty</a> applied as a therapeutic measure (see below). Angioplasty requires extensive skill, especially in emergency settings, and may not always be available out of hours. It is commonly performed by <a href="/wiki/Interventional_cardiology" id="w">interventional cardiologists</a>.</p>
<a id="Histopathology" name="Histopathology"></a><h2>Histopathology</h2>
<p><div style="wigth:300px"><a class="internal" href="/wiki/Image:300px-Myocardial_infarct_emmolition_phase_histopathology.jpg" title="Microscopy image (magn. ca 100x, [[H&#38;E stain]]) from autopsy specimen of myocardial infarct (7 days post-infarction)."><img src="http://en.wikipedia.org/wiki/300px-Myocardial_infarct_emmolition_phase_histopathology.jpg" alt="Microscopy image (magn. ca 100x, [[H&#38;E stain]]) from autopsy specimen of myocardial infarct (7 days post-infarction)." title="Microscopy image (magn. ca 100x, [[H&#38;E stain]]) from autopsy specimen of myocardial infarct (7 days post-infarction)." class="location-none type-thumb" width="300px" />
</a>
<div class="thumbcaption">Microscopy image (magn. ca 100x, <a href="/wiki/H%26amp%3BE_stain" id="w">H&#38;E stain</a>) from autopsy specimen of myocardial infarct (7 days post-infarction).</div></div>

<a href="/wiki/Anatomical_pathology" id="w">Histopathological</a> examination of the heart may reveal infarction at autopsy. Under the microscope, myocardial infarction presents as a circumscribed area of ischemic, coagulative <a href="/wiki/Necrosis" id="w">necrosis</a> (cell death). On gross examination, the infarct is not identifiable within the first 12 hours.<sup id="_ref-rubin546_a" class="reference"><a href="#_note-rubin546" title="">[67]</a></sup></p>
<p>Although earlier changes can be discerned using <a href="/wiki/Electron_microscopy" id="w">electron microscopy</a>, one of the earliest changes under a normal microscope are so-called <i>wavy fibers</i>.<sup id="_ref-Eichbaum1975_a" class="reference"><a href="#_note-Eichbaum1975" title="">[68]</a></sup> Subsequently, the myocyte <a href="/wiki/Cytoplasm" id="w">cytoplasm</a> becomes more <a href="/wiki/Eosinophilic" id="w">eosinophilic</a> (pink) and the cells lose their transversal striations, with typical changes and eventually loss of the <a href="/wiki/Cell_nucleus" id="w">cell nucleus</a>.<sup id="_ref-histopathologyIndia_a" class="reference"><a href="#_note-histopathologyIndia" title="">[69]</a></sup> The interstitium at the margin of the infarcted area is initially infiltrated with <a href="/wiki/Neutrophil" id="w">neutrophils</a>, then with <a href="/wiki/Lymphocyte" id="w">lymphocytes</a> and <a href="/wiki/Macrophage" id="w">macrophages</a>, who <a href="/wiki/Phagocytosis" id="w">phagocytose</a> (&#34;eat&#34;) the myocyte debris. The necrotic area is surrounded and progressively invaded by <a href="/wiki/Granulation_tissue" id="w">granulation tissue</a>, which will replace the infarct with a fibrous (<a href="/wiki/Collagen" id="w">collagenous</a>) <a href="/wiki/Scar" id="w">scar</a> (which are typical steps in <a href="/wiki/Wound_healing" id="w">wound healing</a>). The interstitial space (the space between cells outside of blood vessels) may be infiltrated with <a href="/wiki/Red_blood_cell" id="w">red blood cells</a>.<sup id="_ref-rubin546_b" class="reference"><a href="#_note-rubin546" title="">[67]</a></sup></p>
<p>These features can be recognized in cases where the perfusion was not restored; reperfused infarcts can have other hallmarks, such as contraction band necrosis.<sup id="_ref-Fishbein-1990_a" class="reference"><a href="#_note-Fishbein-1990" title="">[70]</a></sup></p>
<a id="First_aid" name="First_aid"></a><h1> First aid </h1>
<p>As myocardial infarction is a common medical emergency, the signs are often part of <a href="/wiki/First_aid" id="w">first aid</a> courses. The <a href="/wiki/Emergency_action_principles" id="w">emergency action principles</a> also apply in the case of myocardial infarction.</p>
<a id="Immediate_care" name="Immediate_care"></a><h2>Immediate care</h2>
<p>When symptoms of myocardial infarction occur, people wait an average of three hours, instead of doing what is recommended: <a href="/wiki/Call_for_help" id="w">calling for help</a> immediately.<sup id="_ref-FirstAid_a" class="reference"><a href="#_note-FirstAid" title="">[71]</a></sup><sup id="_ref-ActInTime_a" class="reference"><a href="#_note-ActInTime" title="">[72]</a></sup> Acting immediately by calling the emergency services can prevent sustained damage to the heart (&#34;time is muscle&#34;).<sup id="_ref-TimeIsMuscle_a" class="reference"><a href="#_note-TimeIsMuscle" title="">[73]</a></sup></p>
<p>Certain positions allow the patient to rest in a position which minimizes breathing difficulties. A half-sitting position with knees bent is often recommended. Access to more oxygen can be given by opening the window and widening the collar for easier breathing. </p>
<p><a href="/wiki/Aspirin" id="w">Aspirin</a> can be given quickly (if the patient is not <a href="/wiki/Allergy" id="w">allergic</a> to aspirin); but taking aspirin before calling the <a href="/wiki/Emergency_medical_services" id="w">emergency medical services</a> may be associated with unwanted delay.<sup id="_ref-Brown-2000_a" class="reference"><a href="#_note-Brown-2000" title="">[74]</a></sup> Aspirin has an <a href="/wiki/Antiplatelet_drug" id="w">antiplatelet</a> effect which inhibits formation of further <a href="/wiki/Thrombus" id="w">thrombi</a> (blood clots) that clog arteries. <a href="/wiki/Enteric_coating" id="w">Non-enteric coated</a> or soluble preparations are preferred. If chewed or dissolved, respectively, they can be <a href="/wiki/Absorption_(pharmacokinetics)" id="w">absorbed</a> by the body even quicker. If the patient cannot swallow, the aspirin can be used sublingually. U.S. guidelines recommend a dose of 162 â 325 mg.<sup id="_ref-Antman-2004_a" class="reference"><a href="#_note-Antman-2004" title="">[75]</a></sup> Australian guidelines recommend a dose of 150 â 300 mg.<sup id="_ref-Rossi_a" class="reference"><a href="#_note-Rossi" title="">[76]</a></sup></p>
<p><a href="/wiki/Glyceryl_trinitrate_(pharmacology)" id="w">Glyceryl trinitrate</a> (nitroglycerin) <a href="/wiki/Sublingual" id="w">sublingually</a> (under the tongue) can be given if it has been prescribed for the patient.</p>
<p>If an Automated External Defibrillator (AED) is available the rescuer should immediately bring the AED to the patient&#39;s side and be prepared to follow its instructions should the victim lose consciousness. </p>
<p>If possible the rescuer should obtain basic information from the victim, in case the patient is unable to answer questions once <a href="/wiki/Emergency_medical_technician" id="w">emergency medical technicians</a> arrive (if the patient becomes unconscious). The victim&#39;s name and any information regarding the nature of the victims pain will useful to health care providers. Also the exact time that these symptoms started, what the patient was doing at the onset of symptoms, and anything else that might give clues to the pathology of the chest pain. It is also very important to relay any actions that have been taken, such as the number or dose of aspirin or nitroglycerin given, to the EMS personnel.</p>
<p>Other general first aid principles include monitoring pulse, breathing, level of consciousness and, if possible, the blood pressure of the patient. In case of <a href="/wiki/Cardiac_arrest" id="w">cardiac arrest</a>, <a href="/wiki/Cardiopulmonary_resuscitation" id="w">cardiopulmonary resuscitation</a> (CPR) can be administered.</p>
<a id="Automatic_external_defibrillation_(AED)" name="Automatic_external_defibrillation_(AED)"></a><h2>Automatic external defibrillation (AED)</h2>
<p>Since the publication of data showing that the availability of <a href="/wiki/Automated_external_defibrillator" id="w">automated external defibrillators</a> (AEDs) in public places may significantly increase chances of survival, many of these have been installed in public buildings, <a href="/wiki/Public_transport" id="w">public transport</a> facilities, and in non-ambulance emergency vehicles (e.g. <a href="/wiki/Police_car" id="w">police cars</a> and <a href="/wiki/Fire_apparatus" id="w">fire engines</a>). AEDs analyze the heart&#39;s rhythm and determine whether the rhythm is amenable to <a href="/wiki/Defibrillation" id="w">defibrillation</a> (&#34;shockable&#34;), as in   <a href="/wiki/Ventricular_tachycardia" id="w">ventricular tachycardia</a> and <a href="/wiki/Ventricular_fibrillation" id="w">ventricular fibrillation</a>.</p>
<a id="Emergency_services" name="Emergency_services"></a><h2>Emergency services</h2>
<p><a href="/wiki/Emergency_medical_services" id="w">Emergency Medical Services</a> (EMS) Systems vary considerably in their ability to evaluate and treat patients with suspected acute myocardial infarction. Some provide as little as first aid and early defibrillation. Others employ highly trained paramedics with sophisticated technology and advanced protocols.<sup id="_ref-ACC_AHA_STEMI_a" class="reference"><a href="#_note-ACC_AHA_STEMI" title="">[77]</a></sup> Early access to <a href="/wiki/Emergency_medical_services" id="w">EMS</a> is promoted by a 9-1-1 system currently available to 90% of the population in the United States.<sup id="_ref-ACC_AHA_STEMI_b" class="reference"><a href="#_note-ACC_AHA_STEMI" title="">[77]</a></sup> Most are capable of providing <a href="/wiki/Oxygen" id="w">oxygen</a>, IV access, sublingual <a href="/wiki/Nitroglycerine" id="w">nitroglycerine</a>, <a href="/wiki/Morphine" id="w">morphine</a>, and <a href="/wiki/Aspirin" id="w">aspirin</a>. Some are capable of providing <a href="/wiki/Thrombolysis" id="w">thrombolytic therapy</a> in the prehospital setting.<sup id="_ref-ER_TIMI_19_a" class="reference"><a href="#_note-ER_TIMI_19" title="">[78]</a></sup><sup id="_ref-Morrison-2000_a" class="reference"><a href="#_note-Morrison-2000" title="">[79]</a></sup></p>
<p>With <a href="/wiki/Percutaneous_coronary_intervention" id="w">primary PCI</a> emerging as the preferred therapy for ST segment elevation myocardial infarction, <a href="/wiki/Emergency_medical_services" id="w">EMS</a> can play a key role in reducing <a href="/wiki/Door_to_balloon" id="w">door to balloon</a> intervals (the time from presentation to a hospital <a href="/wiki/Emergency_department" id="w">ER</a> to the restoration of coronary artery blood flow) by performing a 12 lead <a href="/wiki/ECG" id="w">ECG</a> in the field and using this information to triage the patient to the most appropriate medical facility.<sup id="_ref-80" class="reference"><a href="#_note-80" title="">[80]</a></sup><sup id="_ref-EMS_PCI_Boston_a" class="reference"><a href="#_note-EMS_PCI_Boston" title="">[81]</a></sup><sup id="_ref-EMS_PCI_a" class="reference"><a href="#_note-EMS_PCI" title="">[82]</a></sup><sup id="_ref-PCI_STEMI_National_Policy_a" class="reference"><a href="#_note-PCI_STEMI_National_Policy" title="">[83]</a></sup> In addition, the 12 lead ECG can be transmitted to the receiving hospital, which enables time saving decisions to be made prior to the patient&#39;s arrival. This may include a &#34;cardiac alert&#34; or &#34;STEMI alert&#34; that calls in off duty personnel in areas where the <a href="/wiki/Coronary_catheterization" id="w">cardiac cath lab</a> is not staffed 24 hours a day.<sup id="_ref-84" class="reference"><a href="#_note-84" title="">[84]</a></sup>  Even in the absence of a formal alerting program, prehospital 12 lead ECGs are independently associated with reduced door to treatment intervals in the emergency department.<sup id="_ref-Cannon_176_a" class="reference"><a href="#_note-Cannon_176" title="">[85]</a></sup></p>
<a id="Wilderness_first_aid" name="Wilderness_first_aid"></a><h2>Wilderness first aid</h2>
<p>In <a href="/wiki/Wilderness_first_aid" id="w">wilderness first aid</a>, a possible heart attack justifies <a href="/wiki/Patient_evacuation" id="w">evacuation</a> by the fastest available means, including <a href="/wiki/MEDEVAC" id="w">MEDEVAC</a>, even in the earliest or precursor stages. The patient will rapidly be incapable of further exertion and have to be carried out.</p>
<a id="Air_travel" name="Air_travel"></a><h2>Air travel</h2>
<p>Certified personnel traveling by commercial aircraft may be able to assist an MI patient by using the on-board <a href="/wiki/First_aid_kit" id="w">first aid kit</a>, which may contain some cardiac drugs (such as <a href="/wiki/Glyceryl_trinitrate" id="w">glyceryl trinitrate</a> spray, <a href="/wiki/Aspirin" id="w">aspirin</a>, or <a href="/wiki/Opioid" id="w">opioid</a> painkillers) and <a href="/wiki/Oxygen" id="w">oxygen</a>. Pilots may divert the flight to land at a nearby airport. <a href="/wiki/Cardiac_monitors" id="w">Cardiac monitors</a> are being introduced by some airlines, and they can be used by both on-board and ground-based physicians.<sup id="_ref-aircraft_a" class="reference"><a href="#_note-aircraft" title="">[86]</a></sup></p>
<a id="Treatment" name="Treatment"></a><h1> Treatment </h1>
<p>A heart attack is a <a href="/wiki/Medical_emergency" id="w">medical emergency</a> which demands both immediate attention and activation of the <a href="/wiki/Emergency_medical_services" id="w">emergency medical services</a>. The ultimate goal of the management in the acute phase of the disease is to salvage as much myocardium as possible and prevent further complications. As time passes, the risk of damage to the heart muscle increases; hence the phrase that in myocardial infarction, &#34;time is muscle,&#34; and time wasted is muscle lost.<sup id="_ref-TimeIsMuscle_b" class="reference"><a href="#_note-TimeIsMuscle" title="">[73]</a></sup></p>
<p>The treatments itself may have complications. If attempts to restore the blood flow are initiated after a critical period of only a few hours, the result is <a href="/wiki/Reperfusion_injury" id="w">reperfusion injury</a> instead of amelioration.<sup id="_ref-Faxon2005_a" class="reference"><a href="#_note-Faxon2005" title="">[87]</a></sup> Other treatment modalities may also cause complications; the use of antithrombotics for example carries an increased risk of <a href="/wiki/Bleeding" id="w">bleeding</a>.</p>
<a id="First_line" name="First_line"></a><h2>First line</h2>
<p><a href="/wiki/Oxygen_first_aid" id="w">Oxygen</a>, <a href="/wiki/Aspirin" id="w">aspirin</a>, <a href="/wiki/Glyceryl_trinitrate_(pharmacology)" id="w">glyceryl trinitrate</a> (nitroglycerin) and <a href="/wiki/Analgesia" id="w">analgesia</a> (usually <a href="/wiki/Morphine" id="w">morphine</a>, hence the popular <a href="/wiki/Mnemonic" id="w">mnemonic</a> <i>MONA</i>, <i>morphine, oxygen, nitro, aspirin</i>) are administered as soon as possible. In many areas, first responders can be trained to administer these prior to arrival at the hospital. Morphine is the preferred pain relief drug due to its ability to dilate blood vessels, which aids in blood flow to the heart as well as its pain relief properties.</p>
<p>Of the first line agents, only aspirin has been proven to decrease <a href="/wiki/Death" id="w">mortality</a>.<sup id="_ref-Lancet1988-ISIS2_a" class="reference"><a href="#_note-Lancet1988-ISIS2" title="">[88]</a></sup></p>
<p>Once the diagnosis of myocardial infarction is confirmed, other pharmacologic agents are often given.  These include <a href="/wiki/Beta_blocker" id="w">beta blockers</a>,<sup id="_ref-ISIS-1_a" class="reference"><a href="#_note-ISIS-1" title="">[89]</a></sup><sup id="_ref-TIMI-2_a" class="reference"><a href="#_note-TIMI-2" title="">[90]</a></sup> anticoagulation (typically with <a href="/wiki/Heparin" id="w">heparin</a>),<sup id="_ref-Antman-2004_b" class="reference"><a href="#_note-Antman-2004" title="">[75]</a></sup> and possibly additional antiplatelet agents such as <a href="/wiki/Clopidogrel" id="w">clopidogrel</a>.<sup id="_ref-Antman-2004_c" class="reference"><a href="#_note-Antman-2004" title="">[75]</a></sup>  These agents are typically not started until the patient is evaluated by an emergency room physician or under the direction of a cardiologist.  These agents can be used regardless of the reperfusion strategy that is to be employed.  While these agents can decrease mortality in the setting of an acute myocardial infarction, they can lead to complications and potentially death if used in the wrong setting.</p>
<a id="Reperfusion" name="Reperfusion"></a><h2>Reperfusion</h2>
<p>The concept of reperfusion has become so central to the modern treatment of acute myocardial infarction, that we are said to be in the reperfusion era.<sup id="_ref-Reperfusion_Era_30_Day_Mortality_a" class="reference"><a href="#_note-Reperfusion_Era_30_Day_Mortality" title="">[91]</a></sup><sup id="_ref-Reperfusion_Era_PAMI_a" class="reference"><a href="#_note-Reperfusion_Era_PAMI" title="">[92]</a></sup> Patients who present with suspected acute myocardial infarction and ST segment elevation (STEMI) or new bundle branch block on the 12 lead <a href="/wiki/ECG" id="w">ECG</a> are presumed to have an occlusive thrombosis in an epicardial coronary artery. They are therefore candidates for immediate reperfusion, either with <a href="/wiki/Thrombolysis" id="w">thrombolytic therapy</a>, <a href="/wiki/Percutaneous_coronary_intervention" id="w">percutaneous coronary intervention</a> (PCI) or when these therapies are unsuccessful, <a href="/wiki/Coronary_artery_bypass_surgery" id="w">bypass surgery</a>. </p>
<p>Individuals without ST segment elevation are presumed to be experiencing either unstable angina (UA) or non-ST segment elevation myocardial infarction (NSTEMI). They receive many of the same initial therapies and are often stabilized with <a href="/wiki/Antiplatelet_drug" id="w">antiplatelet drugs</a> and <a href="/wiki/Anticoagulant" id="w">anticoagulated</a>. If their condition remains (<a href="/wiki/Hemodynamics" id="w">hemodynamically</a>) stable, they can be offered either late <a href="/wiki/Coronary_catheterization" id="w">coronary angiography</a> with subsequent restoration of blood flow (revascularization), or <a href="/wiki/Minimally_invasive_procedure" id="w">non-invasive</a> <a href="/wiki/Cardiac_stress_test" id="w">stress testing</a> to determine if there is significant ischemia that would benefit from revascularization.  If hemodynamic instability develops in individuals with NSTEMIs, they may undergo urgent coronary angiography and subsequent revascularization. The use of thrombolytic agents is contraindicated in this patient subset, however.<sup id="_ref-FTT_Lancet_a" class="reference"><a href="#_note-FTT_Lancet" title="">[93]</a></sup></p>
<p>The basis for this distinction in treatment regimens is that ST segment elevations on an ECG are typically due to complete occlusion of a coronary artery. On the other hand, in NSTEMIs there is typically a sudden narrowing of a coronary artery with preserved (but diminished) flow to the distal myocardium. Anticoagulation and antiplatelet agents are given to prevent the narrowed artery from occluding.</p>
<p>At least 10% of patients with STEMI don&#39;t develop myocardial necrosis (as evidenced by a rise in cardiac markers) and subsequent q waves on EKG after reperfusion therapy. Such a successful restoration of flow to the infarct-related artery during an acute myocardial infarction is known as &#34;aborting&#34; the myocardial infarction. If treated within the hour, about 25% of STEMIs can be aborted.<sup id="_ref-Verheught2006_a" class="reference"><a href="#_note-Verheught2006" title="">[94]</a></sup></p>
<a id="Thrombolytic_therapy" name="Thrombolytic_therapy"></a><h4>Thrombolytic therapy</h4>
<p>{{Main}}
Thrombolytic therapy is indicated for the treatment of STEMI if the drug can be administered within 12 hours of the onset of symptoms, the patient is eligible based on exclusion criteria, and primary PCI is not immediately available.<sup id="_ref-Antman-2004_d" class="reference"><a href="#_note-Antman-2004" title="">[75]</a></sup> The effectiveness of <a href="/wiki/Thrombolysis" id="w">thrombolytic therapy</a> is highest in the first 2 hours. After 12 hours, the risk associated with thrombolytic therapy outweighs any benefit.<sup id="_ref-FTT_Lancet_b" class="reference"><a href="#_note-FTT_Lancet" title="">[93]</a></sup><sup id="_ref-Golden_Hour_Lancet_a" class="reference"><a href="#_note-Golden_Hour_Lancet" title="">[95]</a></sup> Because irreversible injury occurs within 2â4 hours of the infarction, there is a limited window of time available for reperfusion to work. </p>
<p>Thrombolytic drugs are contraindicated for the treatment of unstable angina and NSTEMI<sup id="_ref-FTT_Lancet_c" class="reference"><a href="#_note-FTT_Lancet" title="">[93]</a></sup><sup id="_ref-TIMI_IIIB_a" class="reference"><a href="#_note-TIMI_IIIB" title="">[96]</a></sup> and for the treatment of individuals with evidence of <a href="/wiki/Cardiogenic_shock" id="w">cardiogenic shock</a>.<sup id="_ref-Hochman-1999_a" class="reference"><a href="#_note-Hochman-1999" title="">[97]</a></sup></p>
<p>Although no perfect thrombolytic agent exists, an ideal thrombolytic drug would lead to rapid reperfusion, have a high sustained patency rate, be specific for recent thrombi, be easily and rapidly administered, create a low risk for intra-cerebral and systemic bleeding, have no antigenicity, adverse hemodynamic effects, or clinically significant drug interactions, and be cost effective.<sup id="_ref-Ideal_Thrombolytic_a" class="reference"><a href="#_note-Ideal_Thrombolytic" title="">[98]</a></sup> Currently available thrombolytic agents include <a href="/wiki/Streptokinase" id="w">streptokinase</a>, <a href="/wiki/Urokinase" id="w">urokinase</a>, and <a href="/wiki/Alteplase" id="w">alteplase</a> (recombinant <a href="/wiki/Tissue_plasminogen_activator" id="w">tissue plasminogen activator</a>, rtPA).  More recently, thrombolytic agents similar in structure to rtPA such as <a href="/wiki/Reteplase" id="w">reteplase</a> and <a href="/wiki/Tenecteplase" id="w">tenecteplase</a> have been used. These newer agents boast efficacy at least as good as rtPA with significantly easier administration. The thrombolytic agent used in a particular individual is based on institution preference and the age of the patient.</p>
<p>Depending on the thrombolytic agent being used, <a href="/wiki/Adjuvant" id="w">adjuvant</a> anticoagulation with <a href="/wiki/Heparin" id="w">heparin</a> or <a href="/wiki/Low_molecular_weight_heparin" id="w">low molecular weight heparin</a> may be of benefit.<sup id="_ref-GUSTO-1993-1_a" class="reference"><a href="#_note-GUSTO-1993-1" title="">[99]</a></sup><sup id="_ref-Sabatine-2005_a" class="reference"><a href="#_note-Sabatine-2005" title="">[100]</a></sup> With tPA and related agents (reteplase and tenecteplase), heparin is needed to maintain coronary artery patency. Because of the anticoagulant effect of fibrinogen depletion with streptokinase<sup id="_ref-Cowley-1983_a" class="reference"><a href="#_note-Cowley-1983" title="">[101]</a></sup> and urokinase<sup id="_ref-Lourenco-1989_a" class="reference"><a href="#_note-Lourenco-1989" title="">[102]</a></sup><sup id="_ref-Van de Werf-1986_a" class="reference"><a href="#_note-Van de Werf-1986" title="">[103]</a></sup><sup id="_ref-Bode-1988_a" class="reference"><a href="#_note-Bode-1988" title="">[104]</a></sup> treatment, it is less necessary there.<sup id="_ref-GUSTO-1993-1_b" class="reference"><a href="#_note-GUSTO-1993-1" title="">[99]</a></sup></p>
<p>Intracranial bleeding (ICB) and subsequent <a href="/wiki/Cerebrovascular_accident" id="w">cerebrovascular accident</a> (CVA) is a serious side effect of thrombolytic use.  The risk of ICB is dependent on a number of factors, including a previous episode of intracranial bleed, age of the individual, and the thrombolytic regimen that is being used.  In general, the risk of ICB due to thrombolytic use for the treatment of an acute myocardial infarction is between 0.5 and 1 percent.<sup id="_ref-GUSTO-1993-1_c" class="reference"><a href="#_note-GUSTO-1993-1" title="">[99]</a></sup></p>
<p>Thrombolytic therapy to abort a myocardial infarction is not always effective.  The degree of effectiveness of a thrombolytic agent is dependent on the time since the myocardial infarction began, with the best results occurring if the thrombolytic agent is used within two hours of the onset of symptoms.<sup id="_ref-Boersma-1996_a" class="reference"><a href="#_note-Boersma-1996" title="">[105]</a></sup><sup id="_ref-Morrison-2000_b" class="reference"><a href="#_note-Morrison-2000" title="">[79]</a></sup>  If the individual presents more than 12 hours after symptoms commenced, the risk of intracranial bleed are considered higher than the benefits of the thrombolytic agent.<sup id="_ref-LATE-1993_a" class="reference"><a href="#_note-LATE-1993" title="">[106]</a></sup>  Failure rates of thrombolytics can be as high as 20% or higher.<sup id="_ref-Chesebro-1987_a" class="reference"><a href="#_note-Chesebro-1987" title="">[107]</a></sup> In cases of failure of the thrombolytic agent to open the infarct-related coronary artery, the patient is then either treated conservatively with anticoagulants and allowed to &#34;complete the infarction&#34; or <a href="/wiki/Percutaneous_coronary_intervention" id="w">percutaneous coronary intervention</a> (PCI, see below) is then performed.  Percutaneous coronary intervention in this setting is known as &#34;rescue PCI&#34; or &#34;salvage PCI&#34;. Complications, particularly bleeding, are significantly higher with rescue PCI than with primary PCI due to the action of the thrombolytic agent.</p>
<a id="Percutaneous_coronary_intervention" name="Percutaneous_coronary_intervention"></a><h4>Percutaneous coronary intervention</h4>
<p>{{main}}
<div style="wigth:350px"><a class="internal" href="/wiki/Image:350px-Intracoronary_thrombus.png" title="[[Thrombus]] material (in a cup, upper left corner) removed from a coronary artery during a [[percutaneous coronary intervention]] to abort a myocardial infarction.  Five pieces of thrombus are shown (arrow heads)."><img src="http://en.wikipedia.org/wiki/350px-Intracoronary_thrombus.png" alt="[[Thrombus]] material (in a cup, upper left corner) removed from a coronary artery during a [[percutaneous coronary intervention]] to abort a myocardial infarction.  Five pieces of thrombus are shown (arrow heads)." title="[[Thrombus]] material (in a cup, upper left corner) removed from a coronary artery during a [[percutaneous coronary intervention]] to abort a myocardial infarction.  Five pieces of thrombus are shown (arrow heads)." class="location-right type-thumb" width="350px" />
</a>
<div class="thumbcaption"><a href="/wiki/Thrombus" id="w">Thrombus</a> material (in a cup, upper left corner) removed from a coronary artery during a <a href="/wiki/Percutaneous_coronary_intervention" id="w">percutaneous coronary intervention</a> to abort a myocardial infarction.  Five pieces of thrombus are shown (arrow heads).</div></div>

The benefit of prompt, expertly performed primary percutaneous coronary intervention over thrombolytic therapy for acute ST elevation myocardial infarction is now well established.<sup id="_ref-Keeley-2003_a" class="reference"><a href="#_note-Keeley-2003" title="">[108]</a></sup><sup id="_ref-Grines-1993_a" class="reference"><a href="#_note-Grines-1993" title="">[109]</a></sup><sup id="_ref-GUSTO-IIb_a" class="reference"><a href="#_note-GUSTO-IIb" title="">[110]</a></sup> Logistic and economic obstacles seem to hinder a more widespread application of <a href="/wiki/Angioplasty" id="w">percutaneous coronary intervention</a> (PCI) via <a href="/wiki/Cardiac_catheterization" id="w">cardiac catheterization</a>,<sup id="_ref-Boersma2006_a" class="reference"><a href="#_note-Boersma2006" title="">[111]</a></sup> although the feasibility of regionalized PCI for STEMI is currently being explored in the United States.<sup id="_ref-Rokos_2006_a" class="reference"><a href="#_note-Rokos_2006" title="">[112]</a></sup> The use of percutaneous coronary intervention as a therapy to abort a myocardial infarction is known as primary PCI. The goal of primary PCI is to open the artery as soon as possible, and preferably within 90 minutes of the patient presenting to the emergency room. This time is referred to as the <a href="/wiki/Door-to-balloon" id="w">door-to-balloon</a> time. Few hospitals can provide PCI within the 90 minute interval,<sup id="_ref-Doortoballoon_a" class="reference"><a href="#_note-Doortoballoon" title="">[113]</a></sup> which prompted the American College of Cardiology (ACC) to launch a national Door to Balloon (D2B) Initiative in November of 2006. Over 800 hospitals have joined the D2B Alliance as of March 16, 2007.<sup id="_ref-ACC-D2B_a" class="reference"><a href="#_note-ACC-D2B" title="">[114]</a></sup></p>
<p>The current guidelines in the United States restrict primary PCI to hospitals with available emergency bypass surgery as a backup,<sup id="_ref-Antman-2004_e" class="reference"><a href="#_note-Antman-2004" title="">[75]</a></sup> but this is not the case in other parts of the world.<sup id="_ref-Aversano-2001_a" class="reference"><a href="#_note-Aversano-2001" title="">[115]</a></sup></p>
<p>Primary PCI involves performing a coronary <a href="/wiki/Angiogram" id="w">angiogram</a> to determine the anatomical location of the infarcting vessel, followed by balloon <a href="/wiki/Angioplasty" id="w">angioplasty</a> (and frequently deployment of an intracoronary stent) of the thrombosed arterial segment.  In some settings, an extraction catheter may be used to attempt to aspirate (remove) the thrombus prior to balloon angioplasty.  While the use of intracoronary <a href="/wiki/Stent" id="w">stents</a> do not improve the short term outcomes in primary PCI, the use of stents is widespread because of the decreased rates of procedures to treat restenosis compared to balloon angioplasty.<sup id="_ref-Grines-1999_a" class="reference"><a href="#_note-Grines-1999" title="">[116]</a></sup></p>
<p>Adjuvant therapy during primary PCI include intravenous <a href="/wiki/Heparin" id="w">heparin</a>, <a href="/wiki/Aspirin" id="w">aspirin</a>, and <a href="/wiki/Clopidogrel" id="w">clopidogrel</a>.  The use of <a href="/wiki/Glycoprotein_IIb/IIIa_inhibitor" id="w">glycoprotein IIb/IIIa inhibitors</a> are often used in the setting of primary PCI to reduce the risk of ischemic complications during the procedure.<sup id="_ref-Brener-1998_a" class="reference"><a href="#_note-Brener-1998" title="">[117]</a></sup><sup id="_ref-Tcheng-2003-1_a" class="reference"><a href="#_note-Tcheng-2003-1" title="">[118]</a></sup>  Due to the number of antiplatelet agents and anticoagulants used during primary PCI, the risk of bleeding associated with the procedure are higher than during an elective PCI.<sup id="_ref-119" class="reference"><a href="#_note-119" title="">[119]</a></sup></p>
<a id="Coronary_artery_bypass_surgery" name="Coronary_artery_bypass_surgery"></a><h4>Coronary artery bypass surgery</h4>
<p>{{Main}}
<div style="wigth:300px"><a class="internal" href="/wiki/Image:300px-Coronary_artery_bypass_surgery_Image_657B-PH.jpg" title="&#39;&#39;&#39;Coronary artery bypass surgery&#39;&#39;&#39; during mobilization (freeing) of the [[right coronary artery]] from its surrounding tissue, [[adipose tissue]] (yellow).  The tube visible at the bottom is the aortic cannula (returns blood from the [[Heart-lung machine|HLM]]).  The tube above it (obscured by the [[cardiac surgeon|surgeon]] on the right) is the venous cannula (receives blood from the body).  The patient&#39;s [[heart]] is stopped and the [[aorta]] is cross-clamped.  The patient&#39;s head (not seen) is at the bottom."><img src="http://en.wikipedia.org/wiki/300px-Coronary_artery_bypass_surgery_Image_657B-PH.jpg" alt="&#39;&#39;&#39;Coronary artery bypass surgery&#39;&#39;&#39; during mobilization (freeing) of the [[right coronary artery]] from its surrounding tissue, [[adipose tissue]] (yellow).  The tube visible at the bottom is the aortic cannula (returns blood from the [[Heart-lung machine|HLM]]).  The tube above it (obscured by the [[cardiac surgeon|surgeon]] on the right) is the venous cannula (receives blood from the body).  The patient&#39;s [[heart]] is stopped and the [[aorta]] is cross-clamped.  The patient&#39;s head (not seen) is at the bottom." title="&#39;&#39;&#39;Coronary artery bypass surgery&#39;&#39;&#39; during mobilization (freeing) of the [[right coronary artery]] from its surrounding tissue, [[adipose tissue]] (yellow).  The tube visible at the bottom is the aortic cannula (returns blood from the [[Heart-lung machine|HLM]]).  The tube above it (obscured by the [[cardiac surgeon|surgeon]] on the right) is the venous cannula (receives blood from the body).  The patient&#39;s [[heart]] is stopped and the [[aorta]] is cross-clamped.  The patient&#39;s head (not seen) is at the bottom." class="location-right type-thumb" width="300px" />
</a>
<div class="thumbcaption"><b>Coronary artery bypass surgery</b> during mobilization (freeing) of the <a href="/wiki/Right_coronary_artery" id="w">right coronary artery</a> from its surrounding tissue, <a href="/wiki/Adipose_tissue" id="w">adipose tissue</a> (yellow).  The tube visible at the bottom is the aortic cannula (returns blood from the <a href="/wiki/Heart-lung_machine" id="w">HLM</a>).  The tube above it (obscured by the <a href="/wiki/Cardiac_surgeon" id="w">surgeon</a> on the right) is the venous cannula (receives blood from the body).  The patient&#39;s <a href="/wiki/Heart" id="w">heart</a> is stopped and the <a href="/wiki/Aorta" id="w">aorta</a> is cross-clamped.  The patient&#39;s head (not seen) is at the bottom.</div></div>
</p>
<p>Despite the guidelines, emergency bypass surgery for the treatment of an acute myocardial infarction (MI) is less common then PCI or medical management. In an analysis of patients in the U.S. <a href="/wiki/National_Registry_of_Myocardial_Infarction" id="w">National Registry of Myocardial Infarction</a> (NRMI) from January 1995 to May 2004, the percentage of patients with <a href="/wiki/Cardiogenic_shock" id="w">cardiogenic shock</a> treated with primary PCI rose from 27.4% to 54.4%, while the increase in CABG treatment was only from 2.1% to 3.2%.<sup id="_ref-NRMI_a" class="reference"><a href="#_note-NRMI" title="">[120]</a></sup></p>
<p>Emergency coronary artery bypass graft surgery (CABG) is usually undertaken to simultaneously treat a mechanical complication, such as a ruptured papillary muscle, or a ventricular septal defect, with ensueing cardiogenic shock.<sup id="_ref-Sabiston_a" class="reference"><a href="#_note-Sabiston" title="">[121]</a></sup> In uncomplicated MI, the <a href="/wiki/Mortality_rate" id="w">mortality rate</a> can be high when the surgery is performed immediately following the infarction.<sup id="_ref-Timing1_a" class="reference"><a href="#_note-Timing1" title="">[122]</a></sup> If this option is entertained, the patient should be stabilized prior to surgery, with supportive interventions such as the use of an <a href="/wiki/Intra-aortic_balloon_pump" id="w">intra-aortic balloon pump</a>.<sup id="_ref-Timing2_a" class="reference"><a href="#_note-Timing2" title="">[123]</a></sup> In patients developing cardiogenic shock after a myocardial infarction, both PCI and CABG are satisfactory treatment options, with similar survival rates.<sup id="_ref-SHOCK_a" class="reference"><a href="#_note-SHOCK" title="">[124]</a></sup><sup id="_ref-Hochman-2006_a" class="reference"><a href="#_note-Hochman-2006" title="">[125]</a></sup></p>
<p>Coronary artery bypass surgery involves an artery or vein from the patient being implanted to bypass <a href="/wiki/Stenosis" id="w">narrowings</a> or occlusions on the coronary arteries. Several arteries and veins can be used, however <a href="/wiki/Internal_mammary_artery" id="w">internal mammary artery</a> grafts have demonstrated significantly better long-term patency rates than <a href="/wiki/Great_saphenous_vein" id="w">great saphenous vein</a> grafts.<sup id="_ref-Raja2004_a" class="reference"><a href="#_note-Raja2004" title="">[126]</a></sup> In patients with two or more coronary arteries affected, bypass surgery is associated with higher long-term <a href="/wiki/Survival_rate" id="w">survival rates</a> compared to percutaneous interventions.<sup id="_ref-Hannan2005_a" class="reference"><a href="#_note-Hannan2005" title="">[127]</a></sup> In patients with single vessel disease, surgery is comparably safe and effective, and may be a treatment option in selected cases.<sup id="_ref-Bourassa2000_a" class="reference"><a href="#_note-Bourassa2000" title="">[128]</a></sup> Bypass surgery has higher costs initially, but becomes <a href="/wiki/Cost-effectiveness" id="w">cost-effective</a> in the long term.<sup id="_ref-Hlatky2004_a" class="reference"><a href="#_note-Hlatky2004" title="">[129]</a></sup> A surgical bypass graft is more <a href="/wiki/Invasive_(medical)" id="w">invasive</a> initially but bears less risk of recurrent procedures (but these may be again <a href="/wiki/Minimally_invasive_procedure" id="w">minimally invasive</a>).<sup id="_ref-Bourassa2000_b" class="reference"><a href="#_note-Bourassa2000" title="">[128]</a></sup></p>
<a id="Monitoring_for_arrhythmias" name="Monitoring_for_arrhythmias"></a><h2>Monitoring for arrhythmias</h2>
<p>Additional objectives are to prevent life-threatening arrhythmias or conduction disturbances. This requires monitoring in a <a href="/wiki/Coronary_care_unit" id="w">coronary care unit</a> and protocolised administration of <a href="/wiki/Antiarrhythmic_agent" id="w">antiarrhythmic agents</a>.  Antiarrhythmic agents are typically only given to individuals with life-threatening arrhythmias after a myocardial infarction and not to suppress the <a href="/wiki/Premature_ventricular_contraction" id="w">ventricular ectopy</a> that is often seen after a myocardial infarction.<sup id="_ref-Echt-1991_a" class="reference"><a href="#_note-Echt-1991" title="">[130]</a></sup><sup id="_ref-Waldo-1996_a" class="reference"><a href="#_note-Waldo-1996" title="">[131]</a></sup><sup id="_ref-Julian-1997_a" class="reference"><a href="#_note-Julian-1997" title="">[132]</a></sup></p>
<a id="Rehabilitation" name="Rehabilitation"></a><h2>Rehabilitation</h2>
<p><a href="/wiki/Cardiopulmonary_rehabilitation" id="w">Cardiac rehabilitation</a> aims to optimize function and <a href="/wiki/Quality_of_life" id="w">quality of life</a> in those afflicted with a heart disease. This can be with the help of a physician, or in the form of a cardiac rehabilitation program.<sup id="_ref-NHLBIrecovery_a" class="reference"><a href="#_note-NHLBIrecovery" title="">[133]</a></sup></p>
<p><a href="/wiki/Physical_exercise" id="w">Physical exercise</a> is an important part of <a href="/wiki/Physical_medicine_and_rehabilitation" id="w">rehabilitation</a> after a myocardial infarction, with beneficial effects on cholesterol levels, blood pressure, weight, <a href="/wiki/Stress_(medicine)" id="w">stress</a> and <a href="/wiki/Mood_(psychology)" id="w">mood</a>.<sup id="_ref-NHLBIrecovery_b" class="reference"><a href="#_note-NHLBIrecovery" title="">[133]</a></sup> Some patients become afraid of exercising because it might trigger another infarct.<sup id="_ref-BBCrecovery_a" class="reference"><a href="#_note-BBCrecovery" title="">[134]</a></sup> Patients are stimulated to exercise, and should only avoid certain exerting activities such as shovelling. Local authorities may place limitations on <a href="/wiki/Driving" id="w">driving</a> <a href="/wiki/Motor_vehicle" id="w">motorised vehicles</a>.<sup id="_ref-NovaScotia-DrivingRegulations_a" class="reference"><a href="#_note-NovaScotia-DrivingRegulations" title="">[135]</a></sup>  Some people are afraid to have <a href="/wiki/Human_sexual_behavior" id="w">sex</a> after a heart attack. Most people can resume sexual activities after 3 to 4 weeks. The amount of activity needs to be dosed to the patients possibilities.<sup id="_ref-familyphysician_a" class="reference"><a href="#_note-familyphysician" title="">[136]</a></sup></p>
<a id="Secondary_prevention" name="Secondary_prevention"></a><h2>Secondary prevention</h2>
<p>The risk of a recurrent myocardial infarction decreases with strict blood pressure management and lifestyle changes, chiefly <a href="/wiki/Smoking_cessation" id="w">smoking cessation</a>, regular <a href="/wiki/Physical_exercise" id="w">exercise</a>, a sensible <a href="/wiki/Diet_and_heart_disease" id="w">diet for patients with heart disease</a>, and <a href="/wiki/Alcoholic_beverages_%E2%80%94_recommended_maximum_intake" id="w">limitation of alcohol intake</a>.</p>
<p>Patients are usually commenced on several long-term medications post-MI, with the aim of preventing secondary cardiovascular events such as further myocardial infarctions, <a href="/wiki/Congestive_heart_failure" id="w">congestive heart failure</a> or <a href="/wiki/Cerebrovascular_accident" id="w">cerebrovascular accident</a> (CVA). Unless contraindicated, such medications may include:<sup id="_ref-137" class="reference"><a href="#_note-137" title="">[137]</a></sup><sup id="_ref-Rossi_b" class="reference"><a href="#_note-Rossi" title="">[76]</a></sup></p>

<ul>
<li><a href="/wiki/Antiplatelet_drug" id="w">Antiplatelet drug</a> therapy such as <a href="/wiki/Aspirin" id="w">aspirin</a> and/or <a href="/wiki/Clopidogrel" id="w">clopidogrel</a> should be continued to reduce the risk of plaque rupture and recurrent myocardial infarction. Aspirin is first-line, owing to its low cost and comparable efficacy, with clopidogrel reserved for patients intolerant of aspirin. The combination of clopidogrel and aspirin may further reduce risk of cardiovascular events, however the risk of <a href="/wiki/Hemorrhage" id="w">hemorrhage</a> is increased.<sup id="_ref-Peters-2003_a" class="reference"><a href="#_note-Peters-2003" title="">[138]</a></sup></li>
<li><a href="/wiki/Beta_blocker" id="w">Beta blocker</a> therapy such as <a href="/wiki/Metoprolol" id="w">metoprolol</a> or <a href="/wiki/Carvedilol" id="w">carvedilol</a> should be commenced.<sup id="_ref-Yusuf_a" class="reference"><a href="#_note-Yusuf" title="">[139]</a></sup> These have been particularly beneficial in high-risk patients such as those with <a href="/wiki/Left_ventricle" id="w">left ventricular</a> dysfunction and/or continuing cardiac <a href="/wiki/Ischaemia" id="w">ischaemia</a>.<sup id="_ref-Dargie-2001_a" class="reference"><a href="#_note-Dargie-2001" title="">[140]</a></sup> Î²-Blockers decrease mortality and morbidity. They also improve symptoms of cardiac ischemia in NSTEMI.</li></ul>

<ul>
<li><a href="/wiki/ACE_inhibitor" id="w">ACE inhibitor</a> therapy should be commenced 24â48 hours post-MI in hemodynamically-stable patients, particularly in patients with a history of MI, <a href="/wiki/Diabetes_mellitus" id="w">diabetes mellitus</a>, <a href="/wiki/Hypertension" id="w">hypertension</a>, <a href="/wiki/Anterior" id="w">anterior</a> location of infarct (as assessed by ECG), and/or evidence of left ventricular dysfunction. ACE inhibitors reduce mortality, the development of <a href="/wiki/Heart_failure" id="w">heart failure</a>, and decrease ventricular remodelling post-MI.<sup id="_ref-Pfeffer-1992_a" class="reference"><a href="#_note-Pfeffer-1992" title="">[141]</a></sup></li></ul>

<ul>
<li><a href="/wiki/Statin" id="w">Statin</a> therapy has been shown to reduce mortality and morbidity post-MI.<sup id="_ref-Sacks-1996_a" class="reference"><a href="#_note-Sacks-1996" title="">[142]</a></sup><sup id="_ref-Sacks-1998_a" class="reference"><a href="#_note-Sacks-1998" title="">[143]</a></sup>  The effects of statins may be more than their LDL lowering effects. The general consensus is that statins have <a href="/wiki/Atheroma" id="w">plaque</a> stabilization and multiple other (&#34;pleiotropic&#34;) effects that may prevent myocardial infarction in addition to their effects on blood lipids.<sup id="_ref-Ray2005_a" class="reference"><a href="#_note-Ray2005" title="">[144]</a></sup></li></ul>

<ul>
<li>The <a href="/wiki/Aldosterone_antagonist" id="w">aldosterone antagonist</a> agent <a href="/wiki/Eplerenone" id="w">eplerenone</a> has been shown to further reduce risk of cardiovascular death post-MI in patients with heart failure and left ventricular dysfunction, when used in conjunction with standard therapies above.<sup id="_ref-Pitt_a" class="reference"><a href="#_note-Pitt" title="">[145]</a></sup></li>
<li><a href="/wiki/Omega-3_fatty_acid" id="w">Omega-3 fatty acids</a>, commonly found in fish, have been shown to reduce mortality post-MI.<sup id="_ref-GISSI-Prevenzione-2001_a" class="reference"><a href="#_note-GISSI-Prevenzione-2001" title="">[146]</a></sup>  While the mechanism by which these fatty acids decrease mortality is unknown, it has been postulated that the survival benefit is due to electrical stabilization and the prevention of <a href="/wiki/Ventricular_fibrillation" id="w">ventricular fibrillation</a>.<sup id="_ref-Leaf-2005_a" class="reference"><a href="#_note-Leaf-2005" title="">[147]</a></sup>  However, further studies in a high-risk subset have not shown a clear-cut decrease in potentially fatal arrhythmias due to omega-3 fatty acids.<sup id="_ref-Brouwer-2006_a" class="reference"><a href="#_note-Brouwer-2006" title="">[148]</a></sup><sup id="_ref-Raitt-2005_a" class="reference"><a href="#_note-Raitt-2005" title="">[149]</a></sup></li></ul>
<a id="New_therapies_under_investigation" name="New_therapies_under_investigation"></a><h2>New therapies under investigation</h2>
<p>Patients who receive <a href="/wiki/Stem_cell_treatments" id="w">stem cell treatment</a> by <a href="/wiki/Coronary_artery" id="w">coronary artery</a> injections of <a href="/wiki/Adult_stem_cell" id="w">stem cells</a> derived from their own <a href="/wiki/Bone_marrow" id="w">bone marrow</a> after a myocardial infarction (MI) show improvements in left ventricular <a href="/wiki/Ejection_fraction" id="w">ejection fraction</a> and <a href="/wiki/End-diastolic_volume" id="w">end-diastolic volume</a> not seen with <a href="/wiki/Placebo" id="w">placebo</a>. The larger the initial infarct size, the greater the effect of the infusion.  <a href="/wiki/Clinical_trial" id="w">Clinical trials</a> of <a href="/wiki/Progenitor_cell" id="w">progenitor cell</a> infusion as a treatment approach to ST elevation MI are proceeding.<sup id="_ref-REPAIR2006_a" class="reference"><a href="#_note-REPAIR2006" title="">[150]</a></sup></p>
<p>There are currently 3 <a href="/wiki/Biomaterial" id="w">biomaterial</a> and <a href="/wiki/Tissue_engineering" id="w">tissue engineering</a> approaches for the treatment of MI, but these are in an even earlier stage of <a href="/wiki/Medical_research" id="w">medical research</a>, so many questions and issues need to be addressed before they can be applied to patients. The first involves <a href="/wiki/Polymer" id="w">polymeric</a> left ventricular restraints in the prevention of <a href="/wiki/Heart_failure" id="w">heart failure</a>. The second utilizes <i><a href="/wiki/In_vitro" id="w">in vitro</a></i> engineered cardiac tissue, which is subsequently implanted <i><a href="/wiki/In_vivo" id="w">in vivo</a></i>. The final approach entails injecting cells and/or a scaffold into the myocardium to create <i><a href="/wiki/In_situ" id="w">in situ</a></i> engineered cardiac tissue.<sup id="_ref-biomaterials2006_a" class="reference"><a href="#_note-biomaterials2006" title="">[151]</a></sup></p>
<a id="Complications" name="Complications"></a><h1>Complications</h1>
<p>Complications may occur immediately following the heart attack (in the <a href="/wiki/Acute_(medical)" id="w">acute</a> phase), or may need time to develop (a <a href="/wiki/Chronic_(medicine)" id="w">chronic</a> problem). After an infarction, an obvious complication is a second infarction, which may occur in the domain of another atherosclerotic coronary artery, or in the same zone if there are any live cells left in the infarct.</p>
<a id="Congestive_heart_failure" name="Congestive_heart_failure"></a><h2>Congestive heart failure</h2>
<p>{{Main}}
A myocardial infarction may compromise the function of the heart as a pump for the <a href="/wiki/Circulatory_system" id="w">circulation</a>, a state called <a href="/wiki/Heart_failure" id="w">heart failure</a>. There are different types of heart failure; left- or right-sided (or bilateral) heart failure may occur depending on the affected part of the heart, and it is a low-output type of failure. If one of the heart valves is affected, this may cause dysfunction, such as <a href="/wiki/Mitral_regurgitation" id="w">mitral regurgitation</a> in the case of left-sided MI. The incidence of heart failure is particularly high in patients with diabetes and requires special management strategies.<sup id="_ref-Canto-2000_a" class="reference"><a href="#_note-Canto-2000" title="">[152]</a></sup></p>
<a id="Myocardial_rupture" name="Myocardial_rupture"></a><h2>Myocardial rupture</h2>
<p>{{Main}}
<a href="/wiki/Myocardial_rupture" id="w">Myocardial rupture</a> is most common three to five days after myocardial infarction, commonly of small degree, but may occur one day to three weeks later.  In the modern era of early revascularization and intensive pharmacotherapy as treatment for MI, the incidence of myocardial rupture is about 1% of all MIs.<sup id="_ref-Yip-2003_a" class="reference"><a href="#_note-Yip-2003" title="">[153]</a></sup>  This may occur in the free walls of the <a href="/wiki/Ventricles" id="w">ventricles</a>, the <a href="/wiki/Septum" id="w">septum</a> between them, the <a href="/wiki/Papillary_muscles" id="w">papillary muscles</a>, or less commonly the <a href="/wiki/Atria" id="w">atria</a>. Rupture occurs because of increased pressure against the weakened walls of the heart chambers due to heart muscle that cannot pump blood out effectively. The weakness may also lead to ventricular <a href="/wiki/Aneurysm" id="w">aneurysm</a>, a localized dilation or ballooning of the heart chamber.</p>
<p>Risk factors for myocardial rupture include completion of infarction (no revascularization performed), female sex, advanced age, and a lack of a previous history of myocardial infarction.<sup id="_ref-Yip-2003_b" class="reference"><a href="#_note-Yip-2003" title="">[153]</a></sup>  In addition, the risk of rupture is higher in individuals who are revascularized with a thrombolytic agent than with PCI.<sup id="_ref-Becker-1996_a" class="reference"><a href="#_note-Becker-1996" title="">[154]</a></sup><sup id="_ref-Moreno-2002_a" class="reference"><a href="#_note-Moreno-2002" title="">[155]</a></sup>  The shear stress between the infarcted segment and the surrounding normal myocardium (which may be hypercontractile in the post-infarction period) makes it a nidus for rupture.<sup id="_ref-Shin-1983_a" class="reference"><a href="#_note-Shin-1983" title="">[156]</a></sup></p>
<p>Rupture is usually a catastrophic event that may result a life-threatening process known as <a href="/wiki/Cardiac_tamponade" id="w">cardiac tamponade</a>, in which blood accumulates within the <a href="/wiki/Pericardium" id="w">pericardium</a> or heart sac, and compresses the heart to the point where it cannot pump effectively. Rupture of the intraventricular septum (the muscle separating the left and right ventricles) causes a <a href="/wiki/Ventricular_septal_defect" id="w">ventricular septal defect</a> with <a href="/wiki/Shunt_(medical)" id="w">shunting</a> of blood through the defect from the left side of the heart to the right side of the heart.  Rupture of the papillary muscle may also lead to acute <a href="/wiki/Mitral_regurgitation" id="w">mitral regurgitation</a> and subsequent <a href="/wiki/Pulmonary_edema" id="w">pulmonary edema</a> and possibly even <a href="/wiki/Cardiogenic_shock" id="w">cardiogenic shock</a>.</p>
<a id="Life-threatening_arrhythmia" name="Life-threatening_arrhythmia"></a><h2>Life-threatening arrhythmia</h2>
<p><div style="wigth:300px"><a class="internal" href="/wiki/Image:300px-Electrocardiogram_of_Ventricular_Tachycardia.png" title="A 12 lead [[electrocardiogram]] showing ventricular tachycardia."><img src="http://en.wikipedia.org/wiki/300px-Electrocardiogram_of_Ventricular_Tachycardia.png" alt="A 12 lead [[electrocardiogram]] showing ventricular tachycardia." title="A 12 lead [[electrocardiogram]] showing ventricular tachycardia." class="location-right type-thumb" width="300px" />
</a>
<div class="thumbcaption">A 12 lead <a href="/wiki/Electrocardiogram" id="w">electrocardiogram</a> showing ventricular tachycardia.</div></div>

Since the electrical characteristics of the infarcted tissue change (see <a href="/wiki/Myocardial_infarction#Pathophysiology" id="w">pathophysiology section</a>), <a href="/wiki/Arrhythmias" id="w">arrhythmias</a> are a frequent complication.{{Fact}}  The re-entry phenomenon may cause too fast heart rates (<a href="/wiki/Ventricular_tachycardia" id="w">ventricular tachycardia</a> and even <a href="/wiki/Ventricular_fibrillation" id="w">ventricular fibrillation</a>),{{Fact}} and ischemia in the <a href="/wiki/Electrical_conduction_system_of_the_heart" id="w">electrical conduction system of the heart</a> may cause a <a href="/wiki/Third_degree_heart_block" id="w">complete heart block</a> (when the impulse from the <a href="/wiki/Sinoatrial_node" id="w">sinoatrial node</a>, the normal cardiac pacemaker, doesn&#39;t reach the heart chambers any more).{{Fact}}</p>
<a id="Pericarditis" name="Pericarditis"></a><h2>Pericarditis</h2>
<p>{{Main}}
As a reaction to the damage of the heart muscle, <a href="/wiki/Inflammation" id="w">inflammatory</a> cells are attracted. The inflammation may reach out and affect the heart sac. This is called <a href="/wiki/Pericarditis" id="w">pericarditis</a>. In <a href="/wiki/Dressler%26%2339%3Bs_syndrome" id="w">Dressler&#39;s syndrome</a>, this occurs several weeks after the initial event.</p>
<a id="Cardiogenic_shock" name="Cardiogenic_shock"></a><h2>Cardiogenic shock</h2>
<p>A complication that may occur in the acute setting soon after a myocardial infarction or in the weeks following it is <a href="/wiki/Cardiogenic_shock" id="w">cardiogenic shock</a>.  Cardiogenic shock is defined as a hemodynamic state in which the heart cannot produce enough of a <a href="/wiki/Cardiac_output" id="w">cardiac output</a> to supply an adequate amount of oxygenated blood to the  tissues of the body.</p>
<p>While the data on performing interventions on individuals with cardiogenic shock is sparse, trial data suggests a long-term mortality benefit in undergoing revascularization if the individual is less than 75 years old and if the onset of the acute myocardial infarction is less than 36 hours and the onset of cardiogenic shock is less than 18 hours.<sup id="_ref-Hochman-1999_b" class="reference"><a href="#_note-Hochman-1999" title="">[97]</a></sup>  If the patient with cardiogenic shock is not going to be revascularized, aggressive hemodynamic support is warranted, with insertion of an <a href="/wiki/Intra-aortic_balloon_pump" id="w">intra-aortic balloon pump</a> if not contraindicated.<sup id="_ref-Hochman-1999_c" class="reference"><a href="#_note-Hochman-1999" title="">[97]</a></sup>  If diagnostic coronary angiography does not reveal a culprit blockage that is the cause of the cardiogenic shock, the prognosis is poor.<sup id="_ref-Hochman-1999_d" class="reference"><a href="#_note-Hochman-1999" title="">[97]</a></sup></p>
<a id="Prognosis" name="Prognosis"></a><h1>Prognosis</h1>
<p>The prognosis for patients with myocardial infarction varies greatly, depending on the patient, the condition itself and the given treatment. Using simple <a href="/wiki/Variable" id="w">variables</a> which are immediately available in the <a href="/wiki/Emergency_room" id="w">emergency room</a>, patients with a higher risk of adverse outcome can be identified. For example, one study found that 0.4% of patients with a low risk profile had died after 90 days, whereas the <a href="/wiki/Mortality_rate" id="w">mortality rate</a> in high risk patients was 21.1%.<sup id="_ref-PEPA_a" class="reference"><a href="#_note-PEPA" title="">[157]</a></sup></p>
<p>Although studies differ in the identified variables, some of the more <a href="/wiki/Reproducibility" id="w">reproduced</a> risk stratifiers include age, <a href="/wiki/Hemodynamics" id="w">hemodynamic</a> parameters (such as <a href="/wiki/Heart_failure" id="w">heart failure</a>, <a href="/wiki/Cardiac_arrest" id="w">cardiac arrest</a> on admission, <a href="/wiki/Systole_(medicine)" id="w">systolic</a> <a href="/wiki/Blood_pressure" id="w">blood pressure</a>, or <a href="/wiki/Killip_class" id="w">Killip class</a> of two or greater), ST-segment deviation, <a href="/wiki/Diabetes_mellitus" id="w">diabetes</a>, <a href="/wiki/Blood_plasma" id="w">serum</a> <a href="/wiki/Creatinine" id="w">creatinine</a> concentration, <a href="/wiki/Peripheral_artery_occlusive_disease" id="w">peripheral vascular disease</a> and elevation of cardiac markers.<sup id="_ref-PEPA_b" class="reference"><a href="#_note-PEPA" title="">[157]</a></sup><sup id="_ref-GRACE_a" class="reference"><a href="#_note-GRACE" title="">[158]</a></sup><sup id="_ref-Weir-2006_a" class="reference"><a href="#_note-Weir-2006" title="">[159]</a></sup></p>
<p>Assessment of <a href="/wiki/Left_ventricle" id="w">left ventricular</a> <a href="/wiki/Ejection_fraction" id="w">ejection fraction</a> may increase the predictive power of some risk stratification models.<sup id="_ref-Bosch-2005_a" class="reference"><a href="#_note-Bosch-2005" title="">[160]</a></sup>  The prognostic importance of Q-waves is debated.<sup id="_ref-161" class="reference"><a href="#_note-161" title="">[161]</a></sup> Prognosis is significantly worsened if a mechanical complication (<a href="/wiki/Papillary_muscle" id="w">papillary muscle</a> rupture, myocardial free wall rupture, and so on) were to occur.<sup id="_ref-Becker-1996_b" class="reference"><a href="#_note-Becker-1996" title="">[154]</a></sup></p>
<p>There is evidence that case fatality of myocardial infarction has been improving over the years in all ethnicities.<sup id="_ref-Liew-2006_a" class="reference"><a href="#_note-Liew-2006" title="">[162]</a></sup></p>
<a id="Legal_implications" name="Legal_implications"></a><h1>Legal implications</h1>
<p>At <a href="/wiki/Common_law" id="w">common law</a>, a myocardial infarction is generally a <a href="/wiki/Disease" id="w">disease</a>, but may sometimes be an <a href="/wiki/Injury" id="w">injury</a>. This has implications for no-fault insurance schemes such as <a href="/wiki/Workers%26%2339%3B_compensation" id="w">workers&#39; compensation</a>. A heart attack is generally not covered;<sup id="_ref-prairieview_a" class="reference"><a href="#_note-prairieview" title="">[163]</a></sup> however, it may be a <a href="/wiki/Industrial_injury" id="w">work-related injury</a> if it results, for example, from unusual emotional stress or unusual exertion.<sup id="_ref-biia_a" class="reference"><a href="#_note-biia" title="">[164]</a></sup>  Additionally, in some jurisdictions, heart attacks suffered by persons in particular occupations such as <a href="/wiki/Police_officer" id="w">police officers</a> may be classified as line-of-duty injuries by statute or policy. In some countries or states, a person who has suffered from a myocardial infarction may be prevented from participating in activity that puts other people&#39;s lives at risk, for example driving a car, taxi or airplane.<sup id="_ref-NovaScotia-DrivingRegulations_b" class="reference"><a href="#_note-NovaScotia-DrivingRegulations" title="">[135]</a></sup></p>
<a id="See_also" name="See_also"></a><h1>See also</h1>

<ul>
<li><a href="/wiki/Acute_coronary_syndrome" id="w">acute coronary syndrome</a></li>
<li><a href="/wiki/Angina_pectoris" id="w">angina</a></li>
<li><a href="/wiki/Cardiac_arrest" id="w">Cardiac arrest</a></li>
<li><a href="/wiki/Coronary_thrombosis" id="w">coronary thrombosis</a></li>
<li><a href="/wiki/Hibernating_myocardium" id="w">Hibernating myocardium</a></li>
<li><a href="/wiki/Stunned_myocardium" id="w">Stunned myocardium</a></li>
<li><a href="/wiki/Ventricular_remodeling" id="w">Ventricular remodeling</a></li></ul>
<a id="References" name="References"></a><h1>References</h1>
<p />
<div class="references-small" style="-moz-column-count:2; column-count:2;">
<p /><ol class="references">
<li id="_note-WHO-2002">&uarr; <a href="#_ref-WHO-2002_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-WHO-2002_b" title=""><sup><i><b>b</b></i></sup></a> {{cite book}}</li><li id="_note-2"><b><a href="#_ref-2" title="">&uarr;</a></b> {{cite web}}</li><li id="_note-3"><b><a href="#_ref-3" title="">&uarr;</a></b> {{cite web}}</li><li id="_note-4"><b><a href="#_ref-4" title="">&uarr;</a></b> {{cite web}}</li><li id="_note-5"><b><a href="#_ref-5" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-6"><b><a href="#_ref-6" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-rastPhys">&uarr; <a href="#_ref-rastPhys_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-rastPhys_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-8"><b><a href="#_ref-8" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-9"><b><a href="#_ref-9" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Framingham1998">&uarr; <a href="#_ref-Framingham1998_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Framingham1998_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-Framingham1998_c" title=""><sup><i><b>c</b></i></sup></a> <a href="#_ref-Framingham1998_d" title=""><sup><i><b>d</b></i></sup></a> <a href="#_ref-Framingham1998_e" title=""><sup><i><b>e</b></i></sup></a> <a href="#_ref-Framingham1998_f" title=""><sup><i><b>f</b></i></sup></a> {{cite journal}}</li><li id="_note-11"><b><a href="#_ref-11" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-12"><b><a href="#_ref-12" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Nyboe-1989">&uarr; <a href="#_ref-Nyboe-1989_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Nyboe-1989_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-14"><b><a href="#_ref-14" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Wilson-2006">&uarr; <a href="#_ref-Wilson-2006_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Wilson-2006_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-Wilson-2006_c" title=""><sup><i><b>c</b></i></sup></a> <a href="#_ref-Wilson-2006_d" title=""><sup><i><b>d</b></i></sup></a> {{cite journal}}</li><li id="_note-16"><b><a href="#_ref-16" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-17"><b><a href="#_ref-17" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-18"><b><a href="#_ref-18" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-19"><b><a href="#_ref-19" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-20"><b><a href="#_ref-20" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-21"><b><a href="#_ref-21" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-22"><b><a href="#_ref-22" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-23"><b><a href="#_ref-23" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-24"><b><a href="#_ref-24" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-25"><b><a href="#_ref-25" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-26"><b><a href="#_ref-26" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Saikku-1992">&uarr; <a href="#_ref-Saikku-1992_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Saikku-1992_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-28"><b><a href="#_ref-28" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Alpert-2000">&uarr; <a href="#_ref-Alpert-2000_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Alpert-2000_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-30"><b><a href="#_ref-30" title="">&uarr;</a></b> {{cite web}}</li><li id="_note-rubin525">&uarr; <a href="#_ref-rubin525_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-rubin525_b" title=""><sup><i><b>b</b></i></sup></a> {{cite book}}</li><li id="_note-32"><b><a href="#_ref-32" title="">&uarr;</a></b> {{cite book}}</li><li id="_note-33"><b><a href="#_ref-33" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-34"><b><a href="#_ref-34" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-35"><b><a href="#_ref-35" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-36"><b><a href="#_ref-36" title="">&uarr;</a></b> <a href="/wiki/National_Heart%2C_Lung_and_Blood_Institute" id="w">National Heart, Lung and Blood Institute</a>. <a class="externallink" href="http://www.nhlbi.nih.gov/actintime/haws/haws.htm" rel="nofollow" title="http://www.nhlbi.nih.gov/actintime/haws/haws.htm">Heart Attack Warning Signs</a>. Retrieved November 22, 2006.</li><li id="_note-37"><b><a href="#_ref-37" title="">&uarr;</a></b> <a class="externallink" href="http://www.americanheart.org/presenter.jhtml?identifier=3010002" rel="nofollow" title="http://www.americanheart.org/presenter.jhtml?identifier=3010002">Acute Coronary Syndrome</a>. <a href="/wiki/American_Heart_Association" id="w">American Heart Association</a>. Retrieved November 25, 2006.</li><li id="_note-38"><b><a href="#_ref-38" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-39"><b><a href="#_ref-39" title="">&uarr;</a></b> D Lee, D Kulick, J Marks. <a class="externallink" href="http://www.medicinenet.com/heart_attack/article.htm" rel="nofollow" title="http://www.medicinenet.com/heart_attack/article.htm">Heart Attack (Myocardial Infarction)</a> by MedicineNet.com . Retrieved November 28, 2006.</li><li id="_note-40"><b><a href="#_ref-40" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Diabetologica2004-David">&uarr; <a href="#_ref-Diabetologica2004-David_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Diabetologica2004-David_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-42"><b><a href="#_ref-42" title="">&uarr;</a></b> {{cite book}}</li><li id="_note-43"><b><a href="#_ref-43" title="">&uarr;</a></b> <a class="externallink" href="http://www.gpnotebook.co.uk/simplepage.cfm?ID=892665874&#38;linkID=23278&#38;cook=yes" rel="nofollow" title="http://www.gpnotebook.co.uk/simplepage.cfm?ID=892665874&#38;linkID=23278&#38;cook=yes">Myocardial infarction: diagnosis and investigations</a> - <a href="/wiki/GPnotebook" id="w">GPnotebook</a>, retrieved November 27, 2006.</li><li id="_note-eMedicineEMERG">&uarr; <a href="#_ref-eMedicineEMERG_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-eMedicineEMERG_b" title=""><sup><i><b>b</b></i></sup></a> <i>DE Fenton et al.</i> <a class="externallink" href="http://www.emedicine.com/EMERG/topic327.htm#section~workup" rel="nofollow" title="http://www.emedicine.com/EMERG/topic327.htm#section~workup">Myocardial infarction</a> - <a href="/wiki/EMedicine" id="w">eMedicine</a>, retrieved November 27, 2006.</li><li id="_note-45"><b><a href="#_ref-45" title="">&uarr;</a></b> <a class="externallink" href="http://www.ucl.ac.uk/nuclear-medicine/Patient_Information/Scans/Cardiac.htm" rel="nofollow" title="http://www.ucl.ac.uk/nuclear-medicine/Patient_Information/Scans/Cardiac.htm">HEART SCAN</a> - Patient information from <a href="/wiki/University_College_London" id="w">University College London</a>. Retrieved November 27, 2006.</li><li id="_note-46"><b><a href="#_ref-46" title="">&uarr;</a></b> Gillum RF, Fortmann SP, Prineas RJ, Kottke TE. International diagnostic criteria for acute myocardial infarction and acute stroke. <i>Am Heart J</i> 1984;108:150-8. PMID 6731265</li><li id="_note-emedicine">&uarr; <a href="#_ref-emedicine_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-emedicine_b" title=""><sup><i><b>b</b></i></sup></a> S. Garas <i>et al.</i>. <a class="externallink" href="http://www.emedicine.com/med/topic1567.htm" rel="nofollow" title="http://www.emedicine.com/med/topic1567.htm">Myocardial Infarction</a>. <a href="/wiki/EMedicine" id="w">eMedicine</a>. Retrieved November 22, 2006.</li><li id="_note-48"><b><a href="#_ref-48" title="">&uarr;</a></b> Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. <i>Harrison&#39;s Principles of Internal Medicine</i>. p. 1444. New York: McGraw-Hill, 2005. <a class="external text" href="http://www.amazon.com/exec/obidos/ASIN/0071391401" rel="nofollow" title="http://www.amazon.com/exec/obidos/ASIN/0071391401">ISBN 0-07-139140-1</a>.</li><li id="_note-49"><b><a href="#_ref-49" title="">&uarr;</a></b> Kasper DL, <i>et al.</i> <i>Harrison&#39;s Principles of Internal Medicine</i>. p. 1450.</li><li id="_note-Cannon_175">&uarr; <a href="#_ref-Cannon_175_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Cannon_175_b" title=""><sup><i><b>b</b></i></sup></a> Cannon CP at al. <i>Management of Acute Coronary Syndromes</i>. p. 175. New Jersey: Humana Press, 1999. <a class="external text" href="http://www.amazon.com/exec/obidos/ASIN/0896035522" rel="nofollow" title="http://www.amazon.com/exec/obidos/ASIN/0896035522">ISBN 0-89603-552-2</a>.</li><li id="_note-51"><b><a href="#_ref-51" title="">&uarr;</a></b> Selker HP, Zalenski RJ, Antman EM, et al. &#34;An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: executive summary of a National Heart Attack Alert Program Working Group Report.&#34; <i>Ann Emerg Med</i> 1997; <b>29</b>(1): 25-28. PMID 8998085</li><li id="_note-52"><b><a href="#_ref-52" title="">&uarr;</a></b> Masoudi FA, Magid DJ, Vinson DR et al.&#34;Implications of the Failure to Identify High-Risk Electrocardiogram Findings for the Quality of Care of Patients With Acute Myocardial Infarction.&#34; <i>Circulation</i> 2006; <b>114</b>: 1565-1571.</li><li id="_note-ECC_2005_ACS">&uarr; <a href="#_ref-ECC_2005_ACS_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ECC_2005_ACS_b" title=""><sup><i><b>b</b></i></sup></a> &#34;2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care - Part 8: Stabilization of the Patient With Acute Coronary Syndromes.&#34; <i>Circulation</i> 2005; <b>112</b>: IV-89 - IV-110.</li><li id="_note-54"><b><a href="#_ref-54" title="">&uarr;</a></b> Somers MP, Brady WJ, Perron AD, Mattu A. &#34;The prominent T wave: electrocardiographic differential diagnosis.&#34; <i>Am J Emerg Med</i> 2002; <b>20</b>(3): 243-51. PMID 11992348</li><li id="_note-55"><b><a href="#_ref-55" title="">&uarr;</a></b> Smith SW, Whitwam W. &#34;Acute Coronary Syndromes.&#34; <i>Emerg Med Clin N Am</i> 2006; <b>24(1)</b>: 53-89. PMID 16308113</li><li id="_note-56"><b><a href="#_ref-56" title="">&uarr;</a></b> &#34;The clinical value of the ECG in noncardiac conditions.&#34; <i>Chest</i> 2004; <b>125(4)</b>: 1561-76. PMID 15078775</li><li id="_note-57"><b><a href="#_ref-57" title="">&uarr;</a></b> Brady WJ, Perron AD, Martin ML, Beagle C, Aufderheide TP. &#34;Cause of ST segment abnormality in ED chest pain patients.&#34; <i>Am J Emerg Med</i> 2001; <b>19(1)</b>: 25-8. PMID 11146012</li><li id="_note-ST_Other_MI">&uarr; <a href="#_ref-ST_Other_MI_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ST_Other_MI_b" title=""><sup><i><b>b</b></i></sup></a> Wang K, Asinger RW, Marriott HJ. &#34;ST-segment elevation in conditions other than acute myocardial infarction.&#34; <i>New Engl J Med</i> 2003; <b>349(22)</b>: 2128-35. PMID 14645641</li><li id="_note-59"><b><a href="#_ref-59" title="">&uarr;</a></b> Brady WJ, Chan TC, Pollack M. &#34;Electrocardiographic manifestations: patterns that confound the EKG diagnosis of acute myocardial infarction-left bundle branch block, ventricular paced rhythm, and left ventricular hypertrophy.&#34; <i>J Emerg Med</i> 2000; <b>18(1)</b>: 71-8. PMID 10645842</li><li id="_note-60"><b><a href="#_ref-60" title="">&uarr;</a></b> &#34;Electrocardiographic ST-segment elevation: correct identification of acute myocardial infarction (AMI) and non-AMI syndromes by emergency physicians.&#34; <i>Acad Emerg Med</i> 2001; <b>8(4)</b>: 349-60. PMID 11282670</li><li id="_note-61"><b><a href="#_ref-61" title="">&uarr;</a></b> Sgarbossa EB, Pinski SL, Barbagelata A, Underwood DA, Gates KB, Topol EJ, Califf RM, Wagner GS. &#34;Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle branch block.&#34; <i>N Engl J Med</i> 1996; <b>334</b> (8): 481-7. PMID 8559200</li><li id="_note-62"><b><a href="#_ref-62" title="">&uarr;</a></b> &#34;Electrocardiographic ST-segment elevation: the diagnosis of acute myocardial infarction by morphologic analysis of the ST segment.&#34; <i>Acad Emerg Med</i> 2001; <b>8(10)</b>: 961-7. PMID 11581081</li><li id="_note-63"><b><a href="#_ref-63" title="">&uarr;</a></b> {{cite journal}}<i><a class="externallink" href="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1122768" rel="nofollow" title="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1122768">Full text</a></i></li><li id="_note-64"><b><a href="#_ref-64" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-65"><b><a href="#_ref-65" title="">&uarr;</a></b> {{cite journal}}. <a class="externallink" href="http://www.cmaj.ca/cgi/content/full/167/6/671" rel="nofollow" title="http://www.cmaj.ca/cgi/content/full/167/6/671">Summary for laymen</a></li><li id="_note-66"><b><a href="#_ref-66" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-rubin546">&uarr; <a href="#_ref-rubin546_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-rubin546_b" title=""><sup><i><b>b</b></i></sup></a> {{cite book}}</li><li id="_note-68"><b><a href="#_ref-68" title="">&uarr;</a></b> Eichbaum FW. &#34;&#39;Wavy&#39; myocardial fibers in spontaneous and experimental adrenergic cardiopathies&#34; <i>Cardiology</i> 1975; <b>60</b>(6): 358â65. PMID 782705</li><li id="_note-69"><b><a href="#_ref-69" title="">&uarr;</a></b> S Roy. <a class="externallink" href="http://www.histopathology-india.net/Heart5.htm" rel="nofollow" title="http://www.histopathology-india.net/Heart5.htm">Myocardial infarction</a>. Retrieved November 28, 2006.</li><li id="_note-70"><b><a href="#_ref-70" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-71"><b><a href="#_ref-71" title="">&uarr;</a></b> <a class="externallink" href="http://www.nlm.nih.gov/medlineplus/ency/article/000063.htm" rel="nofollow" title="http://www.nlm.nih.gov/medlineplus/ency/article/000063.htm">Heart attack first aid</a>. <a href="/wiki/MedlinePlus" id="w">MedlinePlus</a>. Retrieved December 3, 2006.</li><li id="_note-72"><b><a href="#_ref-72" title="">&uarr;</a></b> <a class="externallink" href="http://www.nhlbi.nih.gov/actintime/index.htm" rel="nofollow" title="http://www.nhlbi.nih.gov/actintime/index.htm">Act In Time to Heart Attack Signs</a> - <a href="/wiki/NHLBI" id="w">NHLBI</a>. Retrieved December 13, 2006.</li><li id="_note-TimeIsMuscle">&uarr; <a href="#_ref-TimeIsMuscle_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-TimeIsMuscle_b" title=""><sup><i><b>b</b></i></sup></a> <a class="externallink" href="http://www.ehac.org/st-agnes/EHAC_LifeandDeath/TimeisMuscle.htm" rel="nofollow" title="http://www.ehac.org/st-agnes/EHAC_LifeandDeath/TimeisMuscle.htm">TIME IS MUSCLE TIME WASTED IS MUSCLE LOST</a>. Early Heart Attack Care, St. Agnes Healthcare. Retrieved November 29, 2006.</li><li id="_note-74"><b><a href="#_ref-74" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Antman-2004">&uarr; <a href="#_ref-Antman-2004_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Antman-2004_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-Antman-2004_c" title=""><sup><i><b>c</b></i></sup></a> <a href="#_ref-Antman-2004_d" title=""><sup><i><b>d</b></i></sup></a> <a href="#_ref-Antman-2004_e" title=""><sup><i><b>e</b></i></sup></a> {{cite journal}}</li><li id="_note-Rossi">&uarr; <a href="#_ref-Rossi_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Rossi_b" title=""><sup><i><b>b</b></i></sup></a> Rossi S, editor. <a href="/wiki/Australian_Medicines_Handbook" id="w">Australian Medicines Handbook</a> 2006. Adelaide: Australian Medicines Handbook; 2006. <a class="external text" href="http://www.amazon.com/exec/obidos/ASIN/0975791923" rel="nofollow" title="http://www.amazon.com/exec/obidos/ASIN/0975791923">ISBN 0-9757919-2-3</a>.</li><li id="_note-ACC_AHA_STEMI">&uarr; <a href="#_ref-ACC_AHA_STEMI_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-ACC_AHA_STEMI_b" title=""><sup><i><b>b</b></i></sup></a> Antman et al. &#34;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionâExecutive Summary - A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)&#34; <i>J Am Coll Cardiol</i> 2004;44:671-719.</li><li id="_note-78"><b><a href="#_ref-78" title="">&uarr;</a></b> Morrow, Antman, Sayah, et al. &#34;Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.&#34; <i>J Am Coll Cardiol</i> 2002;40(1):71-7. PMID 12103258</li><li id="_note-Morrison-2000">&uarr; <a href="#_ref-Morrison-2000_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Morrison-2000_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-80"><b><a href="#_ref-80" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-81"><b><a href="#_ref-81" title="">&uarr;</a></b> Moyer, Feldman, Levine, et al. &#34;Implications of the Mechanical (PCI) vs Thrombolytic Controversy for ST Segment Elevation Myocardial Infarction on the Organization of Emergency Medical Services: The Boston EMS Experience&#34; <i>Crit Path Cardiol</i> 2004;3:53-61.</li><li id="_note-82"><b><a href="#_ref-82" title="">&uarr;</a></b> Terkelsen, Lassen, Norgaard, et al. &#34;Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutanous coronary intervention&#34; <i>Eur Heart J</i> 2005;26(8):770-7.</li><li id="_note-83"><b><a href="#_ref-83" title="">&uarr;</a></b> Henry, Atkins, Cunningham, et al. &#34;ST-Segment Elevation Myocardial Infarction: Recommendations on Triage of Patients to Heart Attack Centers - Is it Time for a National Policy for the Treatment of ST-Segment Elevation Myocardial Infarction?&#34; <i>J Am Coll Cardiol</i> 2006;47:1339-1345.</li><li id="_note-84"><b><a href="#_ref-84" title="">&uarr;</a></b> Rokos I. and Bouthillet T., <a class="externallink" href="http://www.stemisystems.org/PDF/STEMIsystems_issue2.pdf" rel="nofollow" title="http://www.stemisystems.org/PDF/STEMIsystems_issue2.pdf">&#34;The emergency medical systems-to-balloon (E2B) challenge: building on the foundations of the D2B Alliance,&#34;</a> <i>STEMI Systems</i>, Issue Two, May 2007. Accessed June 16, 2007.</li><li id="_note-85"><b><a href="#_ref-85" title="">&uarr;</a></b> Cannon CP at al. <i>Management of Acute Coronary Syndromes</i>. p. 176. New Jersey: Humana Press, 1999. <a class="external text" href="http://www.amazon.com/exec/obidos/ASIN/0896035522" rel="nofollow" title="http://www.amazon.com/exec/obidos/ASIN/0896035522">ISBN 0-89603-552-2</a>.</li><li id="_note-86"><b><a href="#_ref-86" title="">&uarr;</a></b> Dowdall N. &#34;&#39;Is there a doctor on the aircraft?&#39; Top 10 in-flight medical emergencies.&#34; <i>BMJ</i> 2000; <b>321</b>(7272):1336-7. PMID 11090520. {{PMC}}</li><li id="_note-87"><b><a href="#_ref-87" title="">&uarr;</a></b> Faxon DP. &#34;Coronary interventions and their impact on post myocardial infarction survival.&#34; <i>Clin Cardiol</i> 2005; <b>28</b>(11 Suppl 1):I38-44. PMID 16450811</li><li id="_note-88"><b><a href="#_ref-88" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-89"><b><a href="#_ref-89" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-90"><b><a href="#_ref-90" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-91"><b><a href="#_ref-91" title="">&uarr;</a></b> Lee KL, Woodlief LH, Topol EJ, et al. &#34;Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction.&#34; <i>Circulation</i> 1995; <b>91</b>: 1659-1668. PMID 7882472</li><li id="_note-92"><b><a href="#_ref-92" title="">&uarr;</a></b> Stone GW, Grines CL, Browne KF, et al. &#34;Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trail.&#34; <i>J Am Coll Cardiol</i> 1995; <b>25</b>: 370-377. PMID 14645641</li><li id="_note-FTT_Lancet">&uarr; <a href="#_ref-FTT_Lancet_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-FTT_Lancet_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-FTT_Lancet_c" title=""><sup><i><b>c</b></i></sup></a> &#34;Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists&#39; (FTT) Collaborative Group.&#34; <i>Lancet</i> 1994; <b>343</b>(8893): 311-22. PMID 7905143</li><li id="_note-94"><b><a href="#_ref-94" title="">&uarr;</a></b> Verheugt FW, Gersh BJ, Armstrong PW. &#34;Aborted myocardial infarction: a new target for reperfusion therapy.&#34; <i>Eur Heart J</i> 2006; <b>27</b>(8): 901-4. PMID 16543251</li><li id="_note-95"><b><a href="#_ref-95" title="">&uarr;</a></b> Boersma E, Maas AC, Deckers JW, Simoons ML. &#34;Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour.&#34; <i>Lancet</i> 1996; <b>348</b> (9030): 771-5. PMID 8813982</li><li id="_note-96"><b><a href="#_ref-96" title="">&uarr;</a></b> &#34;Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia.&#34; <i>Circulation</i> 1994; <b>89</b> (4): 1545-56. PMID 8149520</li><li id="_note-Hochman-1999">&uarr; <a href="#_ref-Hochman-1999_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Hochman-1999_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-Hochman-1999_c" title=""><sup><i><b>c</b></i></sup></a> <a href="#_ref-Hochman-1999_d" title=""><sup><i><b>d</b></i></sup></a> {{cite journal}}</li><li id="_note-98"><b><a href="#_ref-98" title="">&uarr;</a></b> White HD, Van de Werf FJ. &#34;Thrombolysis for acute myocardial infarction..&#34; <i>Circulation</i> 1998; <b>97</b> (16): 1632-46. PMID 9593569</li><li id="_note-GUSTO-1993-1">&uarr; <a href="#_ref-GUSTO-1993-1_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-GUSTO-1993-1_b" title=""><sup><i><b>b</b></i></sup></a> <a href="#_ref-GUSTO-1993-1_c" title=""><sup><i><b>c</b></i></sup></a> {{cite journal}}</li><li id="_note-100"><b><a href="#_ref-100" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-101"><b><a href="#_ref-101" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-102"><b><a href="#_ref-102" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-103"><b><a href="#_ref-103" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-104"><b><a href="#_ref-104" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-105"><b><a href="#_ref-105" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-106"><b><a href="#_ref-106" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-107"><b><a href="#_ref-107" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-108"><b><a href="#_ref-108" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-109"><b><a href="#_ref-109" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-110"><b><a href="#_ref-110" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-111"><b><a href="#_ref-111" title="">&uarr;</a></b> Boersma E; The Primary Coronary Angioplasty vs. Thrombolysis Group. &#34;Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients.&#34; <i>Eur Heart J</i> 2006; <b>27</b>(7):779-88. PMID 16513663</li><li id="_note-112"><b><a href="#_ref-112" title="">&uarr;</a></b> Rokos IC, Larson DM, Henry TD, et al.; &#34;Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks.&#34; <i>Am Heart J</i> 2006; <b>152</b>(4):661-7. PMID 16996830</li><li id="_note-113"><b><a href="#_ref-113" title="">&uarr;</a></b> Bradley EH, Herrin J, Wang Y, Barton BA, Webster TR, Mattera JA, Roumanis SA, Curtis JP, Nallamothu BK, Magid DJ, McNamara RL, Parkosewich J, Loeb JM, Krumholz HM. &#34;Strategies for reducing the door-to-balloon time in acute myocardial infarction.&#34; <i>N Engl J Med</i> 2006; <b>355</b>(22): 2308-20. PMID 17101617</li><li id="_note-114"><b><a href="#_ref-114" title="">&uarr;</a></b> {{cite web}}</li><li id="_note-115"><b><a href="#_ref-115" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-116"><b><a href="#_ref-116" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-117"><b><a href="#_ref-117" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-118"><b><a href="#_ref-118" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-119"><b><a href="#_ref-119" title="">&uarr;</a></b> {{cite book}}</li><li id="_note-120"><b><a href="#_ref-120" title="">&uarr;</a></b> Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS; NRMI Investigators. &#34;Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock.&#34; <i>JAMA</i> 2005; 294(4): 448-54. PMID 16046651</li><li id="_note-121"><b><a href="#_ref-121" title="">&uarr;</a></b> {{cite book}}</li><li id="_note-122"><b><a href="#_ref-122" title="">&uarr;</a></b> Kaul TK, Fields BL, Riggins SL, Dacumos GC, Wyatt DA, Jones CR. &#34;Coronary artery bypass grafting within 30 days of an acute myocardial infarction.&#34; <i>Ann Thorac Surg</i> 1995; <b>59(5)</b>: 1169-76. PMID 7733715</li><li id="_note-123"><b><a href="#_ref-123" title="">&uarr;</a></b> Creswell LL, Moulton MJ, Cox JL, Rosenbloom M. &#34;Revascularization after acute myocardial infarction.&#34; <i>Ann Thorac Surg</i> 1995; <b>60(1)</b>: 19-26. PMID 7598589</li><li id="_note-124"><b><a href="#_ref-124" title="">&uarr;</a></b> White HD, Assmann SF, Sanborn TA, Jacobs AK, Webb JG, Sleeper LA, Wong CK, Stewart JT, Aylward PE, Wong SC, Hochman JS. &#34;Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial.&#34; <i>Circulation</i> 2005; <b>112(13)</b>: 1992-2001. PMID 16186436</li><li id="_note-125"><b><a href="#_ref-125" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-126"><b><a href="#_ref-126" title="">&uarr;</a></b> Raja SG, Haider Z, Ahmad M, Zaman H. &#34;Saphenous vein grafts: to use or not to use?&#34; <i>Heart Lung Circ</i> 2004; <b>13</b>(4): 403-9. PMID 16352226</li><li id="_note-127"><b><a href="#_ref-127" title="">&uarr;</a></b> Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. &#34;Long-term outcomes of coronary-artery bypass grafting versus stent implantation.&#34; <i>N Engl J Med</i> 2005; <b>352</b>(21): 2174-83. PMID 15917382</li><li id="_note-Bourassa2000">&uarr; <a href="#_ref-Bourassa2000_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Bourassa2000_b" title=""><sup><i><b>b</b></i></sup></a> Bourassa MG. &#34;Clinical trials of coronary revascularization: coronary angioplasty vs. coronary bypass grafting.&#34; <i>Curr Opin Cardiol</i> 2000; <b>15</b>(4):281-6. PMID 11139092</li><li id="_note-129"><b><a href="#_ref-129" title="">&uarr;</a></b> Hlatky MA, Boothroyd DB, Melsop KA, Brooks MM, Mark DB, Pitt B, Reeder GS, Rogers WJ, Ryan TJ, Whitlow PL, Wiens RD. &#34;Medical costs and quality of life 10 to 12 years after randomization to angioplasty or bypass surgery for multivessel coronary artery disease.&#34; <i>Circulation</i> 2004; <b>110</b>(14):1960-6. PMID 15451795</li><li id="_note-130"><b><a href="#_ref-130" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-131"><b><a href="#_ref-131" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-132"><b><a href="#_ref-132" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-NHLBIrecovery">&uarr; <a href="#_ref-NHLBIrecovery_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-NHLBIrecovery_b" title=""><sup><i><b>b</b></i></sup></a> <a class="externallink" href="http://www.nhlbi.nih.gov/health/dci/Diseases/HeartAttack/HeartAttack_LivingWith.html" rel="nofollow" title="http://www.nhlbi.nih.gov/health/dci/Diseases/HeartAttack/HeartAttack_LivingWith.html">Life after a Heart Attack</a>. U.S. <a href="/wiki/National_Heart%2C_Lung_and_Blood_Institute" id="w">National Heart, Lung and Blood Institute</a>. Retrieved December 2, 2006.</li><li id="_note-134"><b><a href="#_ref-134" title="">&uarr;</a></b> Trisha Macnair. <a class="externallink" href="http://www.bbc.co.uk/health/conditions/heartattackrecovery1.shtml" rel="nofollow" title="http://www.bbc.co.uk/health/conditions/heartattackrecovery1.shtml">Recovering after a heart attack</a>. <a href="/wiki/BBC" id="w">BBC</a>, December 2005. Retrieved December 2, 2006.</li><li id="_note-NovaScotia-DrivingRegulations">&uarr; <a href="#_ref-NovaScotia-DrivingRegulations_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-NovaScotia-DrivingRegulations_b" title=""><sup><i><b>b</b></i></sup></a> {{cite web}}</li><li id="_note-136"><b><a href="#_ref-136" title="">&uarr;</a></b> &#34;<a class="externallink" href="http://familydoctor.org/002.xml" rel="nofollow" title="http://familydoctor.org/002.xml">Heart Attack: Getting Back Into Your Life After a Heart Attack</a>&#34;. <a href="/wiki/American_Academy_of_Family_Physicians" id="w">American Academy of Family Physicians</a>, updated March 2005. Retrieved December 4, 2006.</li><li id="_note-137"><b><a href="#_ref-137" title="">&uarr;</a></b> Smith A, Aylward P, Campbell T, <i>et al.</i> Therapeutic Guidelines: Cardiovascular, 4th edition. North Melbourne: Therapeutic Guidelines; 2003. ISSN 1327-9513</li><li id="_note-138"><b><a href="#_ref-138" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-139"><b><a href="#_ref-139" title="">&uarr;</a></b> Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. <i>Prog Cardiovasc Dis</i> 1985;<b>27</b>:335-71. PMID 2858114</li><li id="_note-140"><b><a href="#_ref-140" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-141"><b><a href="#_ref-141" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-142"><b><a href="#_ref-142" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-143"><b><a href="#_ref-143" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-144"><b><a href="#_ref-144" title="">&uarr;</a></b> Ray KK, Cannon CP. &#34;The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes.&#34; <i>J Am Coll Cardiol</i> 2005;<b>46</b>(8):1425-33. PMID 16226165</li><li id="_note-145"><b><a href="#_ref-145" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-146"><b><a href="#_ref-146" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-147"><b><a href="#_ref-147" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-148"><b><a href="#_ref-148" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-149"><b><a href="#_ref-149" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-150"><b><a href="#_ref-150" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-151"><b><a href="#_ref-151" title="">&uarr;</a></b> Christman KL, Lee RJ. &#34;Biomaterials for the Treatment of Myocardial Infarction&#34;. <i>J Am Coll Cardiol</i> 2006; <b>48</b>(5): 907-13. PMID 16949479</li><li id="_note-152"><b><a href="#_ref-152" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-Yip-2003">&uarr; <a href="#_ref-Yip-2003_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Yip-2003_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-Becker-1996">&uarr; <a href="#_ref-Becker-1996_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-Becker-1996_b" title=""><sup><i><b>b</b></i></sup></a> {{cite journal}}</li><li id="_note-155"><b><a href="#_ref-155" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-156"><b><a href="#_ref-156" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-PEPA">&uarr; <a href="#_ref-PEPA_a" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-PEPA_b" title=""><sup><i><b>b</b></i></sup></a> Lopez de Sa E, Lopez-Sendon J, Anguera I, Bethencourt A, Bosch X; Proyecto de Estudio del Pronostico de la Angina (PEPA) Investigators. &#34;Prognostic value of clinical variables at presentation in patients with non-ST-segment elevation acute coronary syndromes: results of the Proyecto de Estudio del Pronostico de la Angina (PEPA).&#34; <i>Medicine (Baltimore)</i> 2002; <b>81</b>(6): 434-42. PMID 12441900</li><li id="_note-158"><b><a href="#_ref-158" title="">&uarr;</a></b> Fox KA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson FA Jr, Granger CB. &#34;Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE).&#34; <i>BMJ</i> 2006; <b>333</b>(7578):1091. PMID 17032691</li><li id="_note-159"><b><a href="#_ref-159" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-160"><b><a href="#_ref-160" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-161"><b><a href="#_ref-161" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-162"><b><a href="#_ref-162" title="">&uarr;</a></b> {{cite journal}}</li><li id="_note-163"><b><a href="#_ref-163" title="">&uarr;</a></b> <a class="externallink" href="http://www.pvamu.edu/pages/2026.asp" rel="nofollow" title="http://www.pvamu.edu/pages/2026.asp">Workers&#39; Compensation FAQ</a>. <a href="/wiki/Prairie_View_A%26amp%3BM_University" id="w">Prairie View A&#38;M University</a>. Retrieved November 22, 2006.</li><li id="_note-164"><b><a href="#_ref-164" title="">&uarr;</a></b> <a class="externallink" href="http://www.biia.wa.gov/significantdecisions/contents.htm" rel="nofollow" title="http://www.biia.wa.gov/significantdecisions/contents.htm">SIGNIFICANT DECISIONS Subject Index</a>. Board of Industrial Insurance Appeals. Retrieved November 22, 2006.</li></ol></div>

<a id="External_links" name="External_links"></a><h1>External links</h1>
<p>{{Sisterlinks}}
</p>
<ul>
<li><a class="externallink" href="http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=pub" rel="nofollow" title="http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=pub">Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack</a> - based on information of the <a href="/wiki/Framingham_Heart_Study" id="w">Framingham Heart Study</a>, from the United States <a href="/wiki/National_Heart%2C_Lung_and_Blood_Institute" id="w">National Heart, Lung and Blood Institute</a></li>
<li><a class="externallink" href="http://www.nlm.nih.gov/medlineplus/heartattack.html" rel="nofollow" title="http://www.nlm.nih.gov/medlineplus/heartattack.html">Heart Attack</a> - overview of resources from <a href="/wiki/MedlinePlus" id="w">MedlinePlus</a>.</li>
<li><a class="externallink" href="http://ww2.heartandstroke.ca/Page.asp?PageID=1975&#38;ArticleID=5288" rel="nofollow" title="http://ww2.heartandstroke.ca/Page.asp?PageID=1975&#38;ArticleID=5288">Heart Attack Warning Signals</a> from the Heart and Stroke Foundation of Canada</li>
<li><a class="externallink" href="http://www.regionalpci-stemi.org/index.html" rel="nofollow" title="http://www.regionalpci-stemi.org/index.html">Regional PCI for STEMI Resource Center</a> - Evidence based online resource center for the development of regional PCI networks for acute STEMI</li>
<li><a class="externallink" href="http://www.stemisystems.org/" rel="nofollow" title="http://www.stemisystems.org/">STEMI Systems</a> - Articles, profiles, and reviews of the latest publications involved in STEMI care. Quarterly newsletter.</li>
<li><a class="externallink" href="http://d2b.acc.org/" rel="nofollow" title="http://d2b.acc.org/">American College of Cardiology (ACC) Door to Balloon (D2B) Initiative.</a></li>
<li><a class="externallink" href="http://www.americanheart.org/heartattack" rel="nofollow" title="http://www.americanheart.org/heartattack">American Heart Association&#39;s Heart Attack web site</a> - Information and resources for preventing, recognizing and treating heart attack.</li></ul>
<p>{{Circulatory system pathology}}</p>
<p>



</p>

<p><a href="http://ar.wikipedia.org/wiki/Ø§%D8%AD%D8%AA%D8%B4%D8%A7%D8%A1_%D9%82%D9%84%D8%A8%D9%8A">ar:Ø§Ø­ØªØ´Ø§Ø¡ ÙÙØ¨Ù</a>
<a href="http://bg.wikipedia.org/wiki/Ð%D0%BD%D1%84%D0%B0%D1%80%D0%BA%D1%82_%D0%BD%D0%B0_%D0%BC%D0%B8%D0%BE%D0%BA%D0%B0%D1%80%D0%B4%D0%B0">bg:ÐÐ½ÑÐ°ÑÐºÑ Ð½Ð° Ð¼Ð¸Ð¾ÐºÐ°ÑÐ´Ð°</a>
<a href="http://cs.wikipedia.org/wiki/Infarkt_myokardu">cs:Infarkt myokardu</a>
<a href="http://de.wikipedia.org/wiki/Myokardinfarkt">de:Myokardinfarkt</a>
<a href="http://el.wikipedia.org/wiki/Î%CE%BC%CF%86%CF%81%CE%B1%CE%B3%CE%BC%CE%B1_%CF%84%CE%BF%CF%85_%CE%BC%CF%85%CE%BF%CE%BA%CE%B1%CF%81%CE%B4%CE%AF%CE%BF%CF%85">el:ÎÎ¼ÏÏÎ±Î³Î¼Î± ÏÎ¿Ï Î¼ÏÎ¿ÎºÎ±ÏÎ´Î¯Î¿Ï</a>
<a href="http://et.wikipedia.org/wiki/M%C3%BCokardi_infarkt">et:MÃ¼okardi infarkt</a>
<a href="http://es.wikipedia.org/wiki/Infarto_agudo_de_miocardio">es:Infarto agudo de miocardio</a>
<a href="http://eu.wikipedia.org/wiki/Miokardio_infartu_akutu">eu:Miokardio infartu akutu</a>
<a href="http://fr.wikipedia.org/wiki/Infarctus_du_myocarde">fr:Infarctus du myocarde</a>
<a href="http://ko.wikipedia.org/wiki/ì¬%EA%B7%BC%EA%B2%BD%EC%83%89">ko:ì¬ê·¼ê²½ì</a>
<a href="http://hr.wikipedia.org/wiki/Infarkt_miokarda">hr:Infarkt miokarda</a>
<a href="http://id.wikipedia.org/wiki/Serangan_jantung">id:Serangan jantung</a>
<a href="http://it.wikipedia.org/wiki/Infarto_del_miocardio">it:Infarto del miocardio</a>
<a href="http://he.wikipedia.org/wiki/×%D7%AA%D7%A7%D7%A3_%D7%9C%D7%91">he:××ª×§×£ ××</a>
<a href="http://ku.wikipedia.org/wiki/Mirina_mas%C3%BBlkey%C3%AAn_dil">ku:Mirina masÃ»lkeyÃªn dil</a>
<a href="http://la.wikipedia.org/wiki/Infarctus_cordis">la:Infarctus cordis</a>
<a href="http://mk.wikipedia.org/wiki/Ð¡%D1%80%D1%86%D0%B5%D0%B2_%D0%BD%D0%B0%D0%BF%D0%B0%D0%B4">mk:Ð¡ÑÑÐµÐ² Ð½Ð°Ð¿Ð°Ð´</a>
<a href="http://ms.wikipedia.org/wiki/Sakit_jantung">ms:Sakit jantung</a>
<a href="http://nl.wikipedia.org/wiki/Hartaanval">nl:Hartaanval</a>
<a href="http://ja.wikipedia.org/wiki/å¿%E7%AD%8B%E6%A2%97%E5%A1%9E">ja:å¿ç­æ¢å¡</a>
<a href="http://no.wikipedia.org/wiki/Hjerteinfarkt">no:Hjerteinfarkt</a>
<a href="http://pl.wikipedia.org/wiki/Zawa%C5%82_mi%C4%99%C5%9Bnia_sercowego">pl:ZawaÅ miÄÅnia sercowego</a>
<a href="http://pt.wikipedia.org/wiki/Infarto_agudo_do_mioc%C3%A1rdio">pt:Infarto agudo do miocÃ¡rdio</a>
<a href="http://ru.wikipedia.org/wiki/Ð%D1%81%D1%82%D1%80%D1%8B%D0%B9_%D0%B8%D0%BD%D1%84%D0%B0%D1%80%D0%BA%D1%82_%D0%BC%D0%B8%D0%BE%D0%BA%D0%B0%D1%80%D0%B4%D0%B0">ru:ÐÑÑÑÑÐ¹ Ð¸Ð½ÑÐ°ÑÐºÑ Ð¼Ð¸Ð¾ÐºÐ°ÑÐ´Ð°</a>
<a href="http://sq.wikipedia.org/wiki/Infarkti_miokardial">sq:Infarkti miokardial</a>
<a href="http://sr.wikipedia.org/wiki/Ð¡%D1%80%D1%87%D0%B0%D0%BD%D0%B8_%D1%83%D0%B4%D0%B0%D1%80">sr:Ð¡ÑÑÐ°Ð½Ð¸ ÑÐ´Ð°Ñ</a>
<a href="http://fi.wikipedia.org/wiki/Syd%C3%A4ninfarkti">fi:SydÃ¤ninfarkti</a>
<a href="http://sv.wikipedia.org/wiki/Hj%C3%A4rtinfarkt">sv:HjÃ¤rtinfarkt</a>
<a href="http://ur.wikipedia.org/wiki/Ø§%D8%AD%D8%AA%D8%B4%D8%A7%D8%A1_%D8%B9%D8%B6%D9%84_%D9%82%D9%84%D8%A8">ur:Ø§Ø­ØªØ´Ø§Ø¡ Ø¹Ø¶Ù ÙÙØ¨</a>
<a href="http://vi.wikipedia.org/wiki/Nh%E1%BB%93i_m%C3%A1u_c%C6%A1_tim">vi:Nhá»i mÃ¡u cÆ¡ tim</a>
<a href="http://tr.wikipedia.org/wiki/Miyokardiyal_enfarkt%C3%BCs">tr:Miyokardiyal enfarktÃ¼s</a>
<a href="http://uk.wikipedia.org/wiki/Ð%D0%BE%D1%81%D1%82%D1%80%D0%B8%D0%B9_%D1%96%D0%BD%D1%84%D0%B0%D1%80%D0%BA%D1%82_%D0%BC%D1%96%D0%BE%D0%BA%D0%B0%D1%80%D0%B4%D1%83">uk:ÐÐ¾ÑÑÑÐ¸Ð¹ ÑÐ½ÑÐ°ÑÐºÑ Ð¼ÑÐ¾ÐºÐ°ÑÐ´Ñ</a>
<a href="http://yi.wikipedia.org/wiki/×%D7%90%D7%A8%D7%A5_%D7%90%D7%98%D7%90%D7%A7%D7%A2">yi:×××¨×¥ ××××§×¢</a>
<a href="http://zh.wikipedia.org/wiki/å¿%E8%82%8C%E6%A2%97%E6%AD%BB">zh:å¿èæ¢æ­»</a>
</p>